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ABSTRACT 
Physicians in the emergency department (ED) are facing a number of unique challenges 
in the currently changing healthcare and economic climates.  Dramatic increases in ED patient 
volumes have been noted nationwide with visits related to prescription opioid abuse and misuse 
alone having increased by 111% between 2004 and 2008.  
 Ironically, several challenges ED physicians are facing arise from regulatory and 
economic initiatives which were originally designed for the protection of patients.  Regulatory 
requirements to address pain as the fifth vital sign, along with entities utilizing patient 
satisfaction based reimbursement, have inadvertently created an environment conducive to 
exploitation by the prescription opioid abuser.  
 A literature review revealed an informational gap with regard to the impact economic and 
regulatory factors exert on the management of patients, exhibiting drug seeking behavior, by ED 
physicians.  The lack of available information is the basis for this original research.  A 
descriptive, cross-sectional, non-experimental study was conducted over a two month period 
(October – November, 2013) to elicit opinions of ED physicians regarding the management of 
opioid seeking patients. Respondents were asked to include opinions on factors perceived to 
impact treatment of this patient population.    
 Of the ED physicians surveyed, 71% reported a perceived pressure to prescribe opioids to 
avoid administrative and regulatory criticism and 98% perceive patient satisfaction scores as 
being too highly emphasized by reimbursement entities as a means of evaluating healthcare 
ix 
 
quality.  Rising patient volumes and changes in the healthcare climate were also cited as factors 
impacting management practices when treating patients exhibiting drug seeking behavior.     
Emergency department physicians have a unique role in providing unrestricted access of 
care for the public.  This role, in conjunction with the aforementioned concerns, has served to 
create an environment conducive to the potentiation of prescription opioid misuse and abuse. 
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CHAPTER ONE: INTRODUCTION 
Background of the Problem 
 Ongoing changes in both healthcare and economic climates, have contributed to a 
significant increase in ED patient visits including those exhibiting drug seeking behavior.
 1
  
According to the Centers for Disease Control and Prevention (CDC), between 2004 and 2008, 
ED visits, related to the abuse of prescribed opioids, increased by 111% with a concurrent rise in 
visits for benzodiazepines increasing by 89%.
2
 On July 1, 2011 Florida State Surgeon General 
Frank Farmer, MD declared Florida to be in a public health emergency.  Dr. Farmer stated an 
average of seven deaths occurred daily in Florida due to prescription drug overdose specifically 
prescription opioids and other controlled substances.
3
 In November of this same year, a press 
release was issued by the director of the CDC, Dr. Thomas Frieden, stating “Overdoses 
involving prescription painkillers are at epidemic levels and now kill more Americans than 
heroin and cocaine combined.”4    
Statement of the Problem 
 Several regulatory and economic initiatives, designed for the protection of patients and 
delivery of quality medical care, are now being identified by ED physicians as key challenges in 
the management of patients exhibiting drug seeking behavior.  Other challenges such as 
increased patient volumes and time constraints, subsequent to integration of electronic medical 
records (EMR),
5
 are perceived by ED physicians as decreasing patient interaction as well as the 
ability
6
 to employ prescription opioid abuse identification tools.   
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 The use of patient satisfaction scores, and strategies to reduce overall visit times by 
reimbursing agencies, serve as additional challenges for ED physicians. Patients exhibiting drug 
seeking behavior are often demanding in their requests for drugs, abusive to staff and provide 
inaccurate information due to the nature of their dependency and addiction. This creates an 
ethical dilemma for the ED physician of acquiescing to the patient’s demands for the protection 
of staff and other patients.    
Purpose of the Study 
 This purpose of the study was to elicit the opinions of practicing ED physicians in an 
effort to determine if economic changes and regulatory factors were perceived as impacting their 
management of patients exhibiting drug seeking behavior.  The lack of available information, as 
evidenced in a literature search of peer-reviewed works, is the basis for this original research.  
Subsequent to analysis, the data will be used to identify and evaluate factors which may have a 
negative impact on treatment of patients exhibiting drug seeking behavior by ED physicians. 
Research Questions 
 Research questions were based upon personal interviews and Medline / internet searches 
for peer reviewed articles on this topic.  The following research questions were formulated:  
1. Do ED physicians report they are pressured to prescribe opioids because of economic 
 influences? 
2. What economic influences do physicians cite as exerting a pressure on them to prescribe 
 opioids?  
3.    What do ED physicians prefer regarding administrative opioid prescribing  protocols?  
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4.    Do ED physicians refrain from utilizing prescription opioid abuse detection 
 methodologies such as Physician Drug Monitoring Programs (PDMP) or drug screening 
 due to economic factors?  
5.    What rationale do ED physicians use with regard to their decision to cite “opioid 
 overdose” on the patient’s record?                                                                                                                                  
6.         Do ED physicians receive formal training on recognition and management of prescription 
 opioid abuse?        
7.        Is there a difference in physician opinions, from those who work for for-profit versus  
not-for- profit  organizations, with regard to economic pressures to prescribe opioids in 
order to maintain patient satisfaction scores?                                                                                                                   
8. Do ED physicians report that training on recognition and management of prescription 
opioid abuse should be part of their training / continuing education? 
9. Do ED physicians report that their volume of patients manifesting “drug seeking” 
 behavior has increased in recent years?  
10. What do ED physicians report with respect to changes in the volume of patients 
 manifesting “drug seeking” behavior that are supported by government insurance such as  
Medicare / Medicaid?    
11. What do ED physicians report about the clarity and appropriateness of regulatory 
 guidelines / statutes regarding pain management for ED patients manifesting “drug 
 seeking” behavior? 
12. What recommendations do ED physicians have for deterring prescription opioid / 
 controlled substance abuse through actions of the ED?                                                                                                    
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13. What do ED physicians report with respect to socioeconomic factors impacting the 
 volume of patients being seen in the ED manifesting “drug seeking” behavior?                                                                            
14.  Do ED physicians have concerns regarding patient complaints to the Board of Medicine, 
for under-treatment of pain, should they decline to prescribe opioids?                                        
15. Are data regarding morbidity / mortality from prescription opioid abuse patients seen in 
the ED influenced by economic factors? 
Hypotheses 
Based upon results from the research questions, and subsequent to a literature search of 
peer-reviewed articles, the following hypotheses were formulated: 
1. Emergency department physicians report that they are pressured to prescribe opioids due 
to economic concerns arising from administrative and regulatory entities. 
2. Emergency department physicians will prefer to have administrative / regulatory opioid 
prescribing protocols for the purpose of protecting them from disciplinary actions. 
3. There will not be a statistically significant difference between ED physicians working in 
for-profit versus nonprofit hospitals with regard to their perceptions of economic 
pressures from administration to prescribe opioids.  
4. Emergency department physicians will cite their failure to use prescription opioid abuse 
identification methodologies is often related to economic factors. 
5. The majority of ED physicians in a convenience sample have not received formal 
training, through either continuing medical education (CME) or medical school/post-
graduate curricula, on recognition and management of prescription opioid abuse in the 
last three years.  
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6. Emergency department physicians will report they are treating an increased volume of 
ED patients manifesting “drug seeking” behavior due to economic and regulatory factors.  
7. There will not be a statistically significant difference between ED physicians working in 
for-profit versus nonprofit hospitals with regard to economic factors (e.g. administrative, 
reimbursement, regulatory) regarding use of prescription opioid abuse identification 
methodologies. 
8. Emergency department  physicians will report a significant rise in patient volume, 
including those with “drug seeking” behavior, over the last two years. 
Significance of the Study  
This original research is being initiated to obtain the opinions of ED physicians regarding 
economic and regulatory factors impacting management of patients exhibiting drug seeking 
behavior.  Once identified, this information could be utilized by medical associations, healthcare 
organizations, regulatory bodies, and public health officials in the development of continuing 
medical education for physicians, curricula for medical schools and residency programs, 
administrative protocols and legislation instrumental to the deterrence of prescription opioid 
abuse. 
Limitations of the Study 
This study employed a survey instrument to assess ED physicians opinions regarding 
management practices when treating patients with “drug seeking” behavior. While self-reporting 
may represent limited accuracy, overall trends and correlations may be helpful in future 
educational endeavors.  Other potential limitations include: 
1. Sampling was limited to ED physicians in Florida and Georgia potentially limiting the 
ability to “generalize” the population and thereby potentiating internal validity errors.  
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2. The number of participants responding was voluntary therefore non-controlled.  
3. The instrument being utilized could be completed online or by written documents, therefore 
the potential for errors could not be controlled by the researcher.  
4. The potential for bias could not be controlled. 
5. As this research is non-experimental, there is no control for extraneous variables.  
6. As a token of appreciation, survey participants were given an opportunity to view an 
approved continuing education presentation, which awarded them 6.5 hours of Category I 
continuing medical education (CME) credit, thereby potentially influencing participation 
response. 
Delimitations of the Study  
1.       External validity was not limited as random selection was used.  
2.       Sample was diverse including a wide arrange of ages, corporate status of employers and 
experience levels. 
Terms 
1. “Drug Seeking” Behavior –  poorly defined but generally includes patients requesting 
narcotic opioids  for pain management who commonly request specific opioids by name; 
are often abusive and demanding to staff; cite lost / stolen prescriptions, have obtained 
narcotic opioids from multiple prescribers in less than prescribed time frames; clinical 
presentation not consistent with reported level of pain, drug screens inconsistent with 
history, arrive in ED after normal business hours for private physicians, et al.  
2. Opioids – a group of synthetic analgesics having morphine-like effects and bind to opioid 
 receptors such as μ (mu), κ (kappa) and δ (delta.)  
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3. Prescription Drug Monitoring Program (PDMP) – a state run database which collects 
 dispensing information on controlled substances. 
4.      “Doctor Shopping”- seeking care from multiple providers, often simultaneously, without 
the knowledge of the primary or subsequent providers. This scenario is often identified in 
persons suffering from a dependency or addiction to an identified medical therapy. 
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CHAPTER TWO:  LITERATURE REVIEW 
 The literature is robust with articles on the rise of prescription opioid abuse and public 
health initiatives for deterring this national epidemic.  This research will seek to gain insight as 
to how changing regulatory and healthcare climates are impacting ED physicians when 
confronted with treating this special patient population.  
Historical Perspective 
 This section will provide a historical perspective on economic and regulatory events 
associated with the prescription opioid abuse epidemic and how they relate to the ED physician.   
 Pharmacologic Culture.  Americans live in a culture which views pharmaceuticals as a 
solution for multiple aspects of life.  The United States is one of the few countries, the other 
being New Zealand, where it is legal to conduct “direct-to-consumer” marketing of 
pharmaceuticals
7
 using media such as television and internet sites to advertise various 
prescription drugs. 
8,9
  In the United States, the number of prescription drugs dispensed in 2011 
was 4.02 billion compared with 3.99 billion in 2010.  The total sales of prescription drugs 
increased from 308.6 billion in 2010 to $319.9 billion in 2011
10
.  The proclivity of Americans for 
pharmaceuticals may result in negative sequelae such as tolerance and potential dependency.    
 Several studies reflect the hypotheses that ED physicians perceive a pressure to prescribe 
drugs, such as antibiotics, to meet patient expectations and maintain patient satisfaction.
10,11
  The 
concerns for overprescribing of antibiotics was recently addressed by a CDC report which cited 
that antibiotic resistance is responsible for an additional $20 billion in healthcare costs annually.  
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Also noted in the report was the fact that 50% of the antibiotics prescribed are unnecessary or 
inappropriately prescribed.
12
   In many ways this parallels the current prescription opioid abuse 
epidemic.  In both public healthcare crises, overuse of antibiotics and overuse of opioid 
analgesics, pharmaceutical agents are being sought from ED physicians.  Prescribing, without 
appropriate need, has led to tremendous costs for healthcare as well as increased morbidity and 
mortality. 
13
 
 The current CDC research on abuse of antibiotics may serve as an opportunity to discover 
more about the abuse of prescription opioids.  Eliciting the prescribing perceptions of ED 
physicians could lead to the development of education constructed to serve the concerns of both 
healthcare crises.   
 Pain as the “Fifth Vital Sign.”   In medicine, the evaluation of “vital signs” is 
considered to be a standard of care upon which further evaluation and / or testing may be 
predicated.  Vital signs include heart rate, blood pressure, respiratory rate and temperature.
14
 On 
November 11, 1996, Dr. James Campbell, president of the American Pain Society (APS), stated 
that physicians should assess pain with the same “zeal” as that of obtaining vital signs: 
Vital Signs are taken seriously. If pain were assessed with the same zeal as other  
vital signs are, it would have a much better chance of being treated properly. We  
need to train doctors and nurses to treat pain as a vital sign. Quality care means  
that pain is measured and treated.
15
 
Dr. Campbell based this on the APS’s position that pain is undertreated.  This condition, referred 
to as oligoanalgesia, was cited by Dr. Campbell as being based on a lack of communication 
between patient and physician.
16
  His presentation reinforced the society’s 1995 initiative which 
introduced the concept of evaluating pain as the “fifth vital sign.”15,17  The word “sign” in this 
10 
 
context is being used in a colloquial fashion.  Webster’s Medical Dictionary defines a sign as 
“objective evidence of disease as observed and interpreted by the physician.”  A symptom is 
defined as “subjective evidence of disease or physical disturbance observed by the patient.”18 
Therefore pain is not objective, but rather a subjective description expressed by the patient. 
In the years immediately following Dr. Campbell’s recommendation, pain was still 
deemed as being undertreated.  Resnick, et al. postulated a number of reasons as to why this 
might be occurring.
19
  These reasons could easily apply to ED physicians as well as those in 
other disciplines.  One of the reasons offered was that pain doesn’t conform to the normal 
scientific approach.  When treating other illnesses and injuries the evidence is often objective 
rather than subjective.   
 Also cited by Resnick et al. is that the etiology of pain is “often poorly understood” and 
therefore pain simply becomes a symptom and not considered as a disease.  Emergency 
department physicians are not in a position to monitor chronic pain and may well not have had 
specialized training in pain management.  The last reason they addressed is that pain is often not 
an easily resolved problem.  This would be applicable for ED physicians as they are not in a 
position to provide full resolution for patients with long term, chronic pain.   
 Pain is one of the most common complaints (42%) heard  from patients presenting to the 
ED.
20
 Yet, without a means of accurately quantifying the patient’s level of pain, ED physicians 
will have to make the determination as to whether they perceive the patient to be a reliable 
source of information.  Patients who suffer with drug dependency or addiction issues are 
frequently desperate and may go to extremes, including criminal behavior in the case of 
addiction, to obtain a prescription for desired drugs.  By definition, addiction is manifested by an 
intense drive to obtain their desired drug to the point of ignoring normal behavioral restraints.  
11 
 
“Doctor shoppers” and patients exhibiting drug seeking behavior commonly misrepresent their 
level of pain, frequency of medication usage, and illegal obtaining of the drug.
21
   
 For the ED physician, the literature contains a good deal of information regarding pain 
management and the initiation of the “fifth vital sign.”  While research supports the utilization of 
this as a tool, there is also research present which deems this tool to be less than successful.  .  
Mularski et al. reported that no change was reported in pain when analyzing responses before 
and after the pain initiative.
22
  The quality of pain care was unchanged between visits before and 
after the pain initiative based upon subjective provider assessment, charted orders to assess pain, 
change in analgesic modalities, initiation of a new analgesic modality, treatment of co-existing 
pain or follow up for referral.  Their findings indicated that even though a pain scale was 
reported initially, care was not received, later pain scale reports were not included in the written 
record, additional assessments were unnoted and no new therapeutic options were evidenced.
 
They acknowledged that increased awareness to utilize the scale could be beneficial but the 
observed results were still a lack of adequate pain management.
 
A significant concern for ED physicians remains the subjective nature of self-assessed 
pain reporting especially when considering the presence of potential dependency and addiction 
issues.  Without being able to quantify pain, and the incorporation of the “fifth vital sign” into 
accreditation requirements, ED physicians are influenced to treat the presence of pain as 
expressed by the patient.  Inadvertently, the “fifth vital sign” may have become a significant 
factor in America’s prescription drug abuse epidemic. 23  
 Declaration of an Epidemic.  Between 1999 and 2010, the sale of prescription opioids 
quadrupled.  In 2010, the non-medical use of opioids in the US, in populations of  ≥12 years, was 
approximated at 4.8%.  The cost to US healthcare is estimated at approximately $72.5 billion 
12 
 
annually.  According to the CDC, “There were enough opioids prescribed in 2010 to ‘medicate 
every American adult with a standard pain treatment dose of 5 mg of hydrocodone taken every 4 
hours for a month.
24  
 In 2007, approximately 100 persons died each day in the US due to a drug 
overdose.  This represented a rate of approximately three times that in 1991.  Since 1999, 
prescription drugs have shown a greater increase in deaths than illicit drugs such as heroin and 
cocaine.
   
Between 2004 and 2008, ED visits in the US, related to the abuse of prescribed opioids, 
increased by 111% with a concurrent rise (89%) in benzodiazepine visits.
2
   In 2009, 1.2 million 
ED visits, representing a 98.4% increase since 2004, were the result of an abuse or misuse of 
prescription drugs.   
 The term “misuse” is identified with a patient who is taking a prescription medication for 
a purpose other than that for which it was originally intended.  This would also include the 
individual taking a prescription drug not prescribed to them personally. Misuse can also be 
characterized as utilizing a drug at a dose and / or manner not prescribed in order for example, to 
receive an amplified effect.   The term “abuse” would refer to an individual taking the drug for 
the sole purpose of the psychological effect or “high” which they might receive after ingestion.   
 Among the most noted of prescription drugs involved were opioid analgesics such as 
oxycodone (Oxycontin), hydrocodone with acetaminophen (Vicodin), hydromorphone 
(Dilaudid), oxycodone with acetaminophen (Percocet) , methadone, and fentanyl (Duragesic).    
 On July 1, 2011 Florida State Surgeon General Frank Farmer, MD declared Florida to be 
in a public health emergency.  Dr. Farmer stated an average of seven deaths occurred daily in 
Florida due to prescription drug overdose specifically prescription opioids and other controlled 
substances.
25
   In November 2011, a press release was issued by the director of the CDC, Dr. 
13 
 
Thomas Frieden, stating “Overdoses involving prescription painkillers are at epidemic levels and 
now kill more Americans than heroin and cocaine combined.”26 
The Impact of Regulatory Actions  
 Joint Commission.  The Joint Commission on the Accreditation of Healthcare 
Organizations (Joint Commission, formerly referred to as JCAHO) was founded in 1951 by a 
number of professional organizations including the American Hospital Association, American 
Medical Association, American College of Physicians and the American College of Surgeons.
27
 
Their mission is to improve healthcare for the public through accreditation and monitoring of US 
hospitals.  The organization awards accreditation to hospitals based upon safety and quality 
assurance recommendations and demonstrated adherence to these standards.  Accreditation is 
voluntary, however, accreditation is of paramount importance to any hospital that receives 
reimbursement from Medicare and Medicaid programs, the organization must meet the standards 
established by the Joint Commission.    
 On January 1, 2001, the Joint Commission, formally included pain management 
standards into their accreditation guidelines
28
 and initiated a campaign, “Pain: The Fifth Vital 
Sign”, into their hospital inspections.29  A review of responses suggest that when this occurred, 
namely management of pain would now be considered as a metric which could affect 
accreditation scores and ultimately reimbursement, physicians have become “more liberal” in 
their opioid prescription practices and thereby increasing the potential prevalence of addiction.
30
 
 Litigation and Case Law.  Subsequent to what is now perceived as an epidemic with 
regard to prescription opioid abuse, a number of legal challenges have occurred with respect to 
what is perceived as the over- and under treatment of pain by physicians.  
14 
 
 In 2001, what was considered to be a landmark case was heard in the Superior Court of 
California.  In Bergman v. Chin
31
, the presiding judge found Dr. Chin guilty of “elder abuse and 
reckless negligence” citing inadequate pain management.  What was significant was the fact that 
the Medical Board of California had already reviewed the case but stated that, although their 
consultant agreed that pain management provided by Dr. Chin was inadequate, they did not find 
sufficient evidence to warrant a disciplinary action.  The jury found in favor of the plaintiff’s 
family and awarded them $1.5 million in damages which was subsequently reduced to $375,000 
but the case drew national attention as a first of its kind.   
 Civil litigation cases have been documented for both over- and under-prescribing.  The 
literature reveals both peer-reviewed articles, and physician websites including social media 
“blogs”, which are robust with physician concerns of potential litigation for prescribing, or 
failing to prescribe adequate analgesia.  The following is a patient quote derived from the 
literature:  “I know I’m addicted to (opioids), and it’s the doctors’ fault because they prescribed 
them. But I’ll sue them if they leave me in pain.”32 
 
In December of 2007, Coombes v Florio was decided by the Massachusetts Supreme 
Judicial court.  The decision “significantly expanded” the scope of what was traditionally 
expected by physicians with regard to the duty toward their patients.
 
The Massachusetts Supreme 
Judicial Court allowed one of the state’s lower courts to preside over a case involving a motor 
vehicle accident in which a child was injured and subsequently died.  The driver was found to be 
under the care of a physician and had been prescribed medications for a multiple of medical 
etiologies.  It was determined that the driver had lost consciousness behind the wheel 
subsequently resulting in the accident.  The victim’s family pursued litigation against the 
physician overseeing care of the driver citing that the driver had not been given adequate 
15 
 
education regarding the potential dangers of driving while under the influence of the stated 
medications.
 33
  The drugs included two drugs with potential central nervous system depression 
specifically Oxycodone and Paxil.  In Coombes v. Florio, 450 Mass. 182 (2007), the Court, 
though divided, maintained that it is the ultimate duty of the physician to provide adequate 
education on the risks of pertinent medication both for the sake of the patient and those 
foreseeably at risk by actions of the patient. 
 A review of LexisNexis revealed no specific cases or case law that has been established 
subsequent to an ED physician being named in litigation for over- or under-prescribing practices.  
Attempts were also made by reviewing the Federation of Boards of Medicine’s website to 
determine if any ED physicians had been reviewed by the various Boards for improper 
prescribing but no evidence was found.   
 Any potential disciplinary action by the BOM could have a negative financial impact on 
ED physicians both personally and professionally
34
 and therefore have a possible impact on 
prescribing practices.   
 Boards of Medicine.   The Board of Medicine (BOM) plays a significant role for all 
physicians in that their position is to educate, license, monitor, rehabilitate and discipline 
physicians within their jurisdiction.  Therefore ED physicians must consider their actions in the 
treatment of patients as complaints are a realistic possibility.   A literature search, query of 
LexisNexis and internet searches have failed to reveal any specific actions taken against ED 
physicians with regard to over / under prescribing of opioids.  However, the literature did reveal 
a rising number of non-ED physician cases being presented to state Boards with complaints of 
inadequate treatment of pain as the basis.   
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 Emergency department physicians should be aware of specific Board requirements within 
their states of practice.  The California Medical Board, for example, had to review current laws 
on prescribing to patients with known addictions, which may be discovered by utilizing the 
state’s PDMP, for the protection of physicians. 35   Under section 2241 of the California Business 
and Professions Code and section 11156 of the California Health and Safety Code, it was 
deemed as unprofessional for physicians to prescribe to an “addict.”   Due to changes in standard 
of care, prescribers are now offered provisions which would allow exclusion to that rule. 
 The Federation of State Boards of Medicine (FSBOM) cites insufficient training of 
physicians in the current guidelines for appropriate pain management, including knowledge of 
medical standards and clinical guidelines drawn from evidence based research, as contributing to 
the prevalence of under treatment of pain. This would be a legitimate concern as research 
supports an inadequate amount of training, if any, being provided as part of medical school 
curricula or in post-graduate training.
36,37 
 
The FSBOM also recognizes that physicians are concerned that prescribing of opioids, 
and other controlled substances, could bring about scrutiny by regulatory agencies such as the 
Drug Enforcement Agency (DEA), local Department of Health (DOH) and law enforcement 
agencies.  Other factors include a lack of knowledge regarding drug dependency and addiction 
syndromes, as well as regulatory policies as they pertain to the physician’s specific state.38
 To assist physicians in their prescribing practices and address some of the 
aforementioned concerns, the FSBOM developed the Model Guidelines for the Use of Controlled 
Substances for the Treatment of Pain.  This publication was formally adopted in April of 1998 
and subsequently distributed to not only the individual state medical boards, but also to other 
medical professional organizations and regulator boards, both federal and state regulatory 
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agencies, pharmaceutical houses, various advocacy groups, physicians and allied health 
providers.  Though not written for ED physicians specifically, this model represents a 
standardization that could supplant an ED physician’s knowledge as well.   
 Emergency Medical Treatment & Labor Act (EMTALA).   ED physicians are greatly 
impacted by EMTALA with regard to patients seeking medical care and demonstrating drug 
seeking behavior.  Unlike their private practice counterparts, ED physicians cannot elect, or 
reject, patients to be seen as part of their practice. As part of the Consolidated Omnibus 
Reconciliation Act (COBRA), Congress passed the Emergency Medical Treatment and Active 
Labor Act (EMTALA) in 1986.   The law was originated to insure access to emergency medical 
treatment and prevent uninsured patients from being transferred from private to public facilities 
due to their inability to afford care.  “Patient dumping” was conducted without consideration of 
the patient’s condition or stability to tolerate the transfer.  It is considered to be one of the 
country’s most comprehensive laws for assuring nondiscriminatory access to emergency 
departments.  Enforcement of EMTALA regulations is overseen by the Centers for Medicare and 
Medicaid Services (CMS).  Even though its initial language focused primarily on emergency 
medicine, EMTALA applies to patient care throughout the hospital and its departments.
39
  
 There are three distinct legal duties imposed by EMTALA yet they only apply to 
facilities participating in Medicare.  However, that encompasses approximately 98% of all US 
hospitals therefore this law has significant impact.  The first law mandates that hospitals perform 
a medical screening examination on all patients presenting to the ED and requesting care to 
determine if an emergency medical condition is present.   Second, if a condition is present, the 
ED staff must either stabilize the condition or, if not possible, must transfer to a facility with 
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appropriate capabilities to manage the patient’s condition.  Third, hospitals known for 
specialized care capabilities are required to accept transfers in need of those services.   
 Unlike their private practice counterparts, ED physicians cannot elect, or reject, patients 
to be seen as part of their practice including those exhibiting drug seeking behavior.  One of the 
strategies being used by ED’s to help deter prescription opioid abuse is the posting of signs 
advising patients of limitations on the prescribing of controlled substances including opioids.  
For example, signs are posted in the Denver Health ED advising patients that the hospital will no 
longer fill prescriptions for long acting opioid prescriptions and will limit prescriptions for short 
term courses of opioids as well.
40
 
 However, when the South Carolina Medical Association attempted to utilize this strategy, 
they received a correspondence from a representative of CMS advising that this could be 
construed as a violation of EMTALA. The following is an excerpt from this communication to 
the South Carolina Medical Association.  The pdf file of this correspondence is posted on the 
Emergency Physicians Monthly, open source website: 
Accordingly, the language regarding ‘Prescribing Pain Medication in the Emergency 
Department’ which you have provided, and any similar language which the hospital 
might choose to post in patient waiting rooms or treatment rooms might be considered to 
be coercive or intimidating to patients who present to the ED with painful medical 
conditions, thereby violating both the language and the intent of the EMTALA statute 
and regulations.
41
 
This type of regulatory communication would be of direct concern to ED physicians and their 
respective hospitals.  As mentioned, CMS oversees the enforcement of EMTALA legislation 
therefore any hospital accepting Medicare patients would be adversely affected if CMS deemed 
19 
 
that a violation of EMTALA had occurred through the posting of these types of communiques in 
the ED.  
 Controlled Substance Prescribing Guidelines and Protocols.  On a federal level, 
concerns regarding lack of clear ED management guidelines were addressed in the White House 
paper.  The Office of National Drug Control Policy (ONDCP) stated it will coordinate with the 
American College of Emergency Physicians (ACEP) in order to “develop evidence-based 
clinical guidelines that establish best practices for opioid prescribing in the Emergency 
Department.”42 
 The Food and Drug Administration (FDA) initiated a strategic initiative known as Risk 
Evaluation and Mitigation Strategy (REMS) in April of 2011.  REMS is being used as a means 
of educating physicians on the risks versus benefits associated with drug products.  The FDA 
required REMS to be provided for those prescribing extended-release and long-acting (ER/LA) 
opioid analgesics.
43 
 
On a state level, ED physicians must be aware of specific guidelines and requirements 
regarding the prescribing of opioids and controlled substances.  Above what is required to obtain 
the DEA license, some states are now requiring CME on prescription opioid abuse, registration 
with the state’s PDMP and / or querying the PDMP prior to the prescribing of opioids or other 
controlled substances.
44
 As an example, in 2001, the Medical Board of California began 
requiring physicians to participate in a one-day pain management course.
45
 
 State guidelines, such as those originated in Washington
46
, address significant topics of 
importance to ED practitioners treating the patient exhibiting drug seeking behavior.  The 
Washington guidelines reiterate the impact that ED’s have with regard to opioid prescribing.  As 
cited in their guidelines: “The emergency department (ED) is the largest ambulatory source for 
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opioid analgesics with 39% of all opioids prescribed, administered, or continued coming from 
emergency departments.”47 First, it is reiterated that the guidelines were originated to assist ED 
physicians in their opioid prescribing practices.  The guidelines also emphasize that “preserving 
the vital role of the ED” is of paramount importance in treating patients needing emergency 
medical care.  Some of the specific points within their guidelines include: 
1. The ED is not the appropriate site to manage chronic pain.  Their guidelines cite 
 repetitive treatment as being “counter-therapeutic” to the patient receiving the most 
 advantageous care. Further stated was the need for pain therapy only in the acute 
 exacerbation of pain with objective findings.  
2. The use of intravenous and intramuscular opioids in the ED is discouraged.  Parenteral 
 opioids only afford short term duration and provide a potential for euphoria. Oral opioids 
 have a more gradual release and therefore longer cessation of pain.  Oral opioids would 
 have a more gradual release and therefore longer cessation of pain.   
3. Lost or stolen prescriptions will not be filled due to the association with opioid abuse and 
 misuse.  Additionally, this could violate a contract with the patient’s pain management 
 specialist.   
4. Opioids will not be administered as a means of replacing methadone doses.  Due to the 
 long half-life, methadone patients are not at risk for developing withdrawal.   
5. As oxycodone and methadone are prevalent in unintentional drug overdoses, they will not 
 be prescribed from the ED.  Long acting opioids require monitoring that is unavailable in 
 the ED therefore will not be given. 
6. Physicians within the ED were encouraged to utilize an internal monitoring program with 
 which they could share information regarding the patient and their history.   The point 
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 was stressed that sharing of information between medical providers who have both 
 administered care for the patient is not a violation of the Health Insurance Portability and 
 Accountability Act (HIPAA).   
7. A working relationship should be established with local pain management physicians 
 specifically in the forwarding of patient “pain” agreements. Having a copy of this 
 directive will assist ED physicians with decisions regarding higher complexities of care. 
8. The ED will require that the patient present a government issued, photo identification 
 card prior to obtaining a script for any opioid.  The stipulation to present the ID will also 
 be printed on the actual computer generated prescription thereby requiring the patient 
 themselves to fill the prescription.  Exceptions were noted within the body of the 
 Washington guidelines. 
9. Their guidelines encouraged taking a photograph of patients should they not be able to 
 present a photo ID.  The photo is attached to the medical record and the writers of the 
 guidelines deemed this to be a potential abuse deterrent. 
10. Emergency department care coordinators are assigned to assist patients in establishing a 
 relationship with a primary care doctor thus negating the need for return visits due to 
 chronic pain. 
11. Emergency department care coordinators will maintain a list of primary care clinics for 
 distribution to patients which frequent the ED. 
12. Use of brief screenings, brief intervention, referral and treatment is included as part of the 
 guidelines.  This strategy has shown to be effective for the Washington participants citing 
 reductions in days of drug use from 41% - 54%.   
13. Administration of Demerol is discouraged due to the possibility of seizure activity.   
22 
 
14. Urine drug testing is encouraged but with the caveat that training in the interpretation of 
 drug screen results is highly suggested.  Drug screening is also suggested for the purpose 
 of identifying patients using illicit drugs and / or not taking medications reportedly 
 prescribed to them.  These scenarios would be sufficient for refusal to prescribe opioids. 
15. Prescribe a limited supply of short acting opioids.  For objective findings such as what 
 would be found in trauma patients, no more than a 30 day supply is recommended.  This 
 discourages delay in seeking appropriate evaluation and follow-up. 
16. Screenings should take place during obtaining of history to determine present or past 
 history of abuse.  For chronic pain, non-opioid analgesics should be offered.  For acute 
 pain in the presence of abuse, opioids would be given cautiously for these patients and 
 subsequent to counsel on deleterious effects from the opioids and addiction. 
17. EMTALA requires a medical screening but the guidelines specify that if an emergency 
 medical condition is not found, there is no obligation on the physician’s part to treat a 
 patient’s pain in the ED.    
Subsequent to the review of these guidelines, there are several points of interest that could merit 
further discussion.  The Washington guidelines serve to meet many of the recommendations 
found in the literature specific to treatment of patients exhibiting drug seeking behavior by ED 
physicians: 
1. Recommendations for limited supplies of short acting opioids. 
2. Screening for abuse. 
3. Strategy of brief screening followed by brief intervention as recommended by ONDCP 
 method.
48
 
4. Limiting parenteral opioid administration. 
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5. Appropriate photo identification required. 
6. Laboratory screening for illicit drugs and absence of prescribed drugs is encouraged as 
 support for refusal to prescribe. 
7. Lost / stolen prescriptions are not replaced, nor are methadone doses. 
8. The reference to EMTALA regarding “severe pain” as not being an “emergency medical 
 condition” could be subject to scrutiny.  In reviewing the aforementioned CMS 
 correspondence to the South Carolina Medical Association, the verbiage is stated:“(e)(1) 
 The term “emergency medical condition” means- (A) a medical condition manifesting 
 itself by acute symptoms of sufficient severity (including severe pain) ….. etc. (emphasis 
 added).
49   ED physicians electing to exercise the option not to treat a patient’s pain due to 
 the lack of emergency medical condition may be influenced by Joint Commission 
 requirements to provide adequate pain relief. 
The Washington guidelines serve to remind ED physicians in other states to be aware of their 
state requirements for prescribing and dispensing.  For example, the state of Washington does 
not require patients to display a photo identification for obtaining opioids but the home state of 
the ED physician might make this stipulation.    
Emergency department physicians should be concerned regarding state laws but also 
municipal requirements.  Physicians must be aware of various statutes such as those requiring 
them to register with the PDMP, receive CME on prescription opioid abuse and or perform a 
query of the PDMP prior to prescribing.
49 
A number of states and individual facilities throughout the United States, such as the ten 
public hospitals in New York City, have enacted administrative opioid prescribing protocols for 
ED’s.  This action serves to deter availability of prescription opioids which may lead to potential 
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abuse.
50,51  
Proponents suggest that opioid prescribing protocols would serve as a protection for 
physicians supporting their decision to prescribe or refuse to prescribe opioids / controlled 
substances to patients exhibiting drug seeking behavior.  Opponents such as Dr. Alex Rosenau, 
president of the American College of Emergency Physicians (ACEP), have concerns of 
“legislative” medicine and its potential to hinder the professional judgment of ED physicians.52   
Dr. Rosenau cited data which stated that ED physicians, “write fewer than 5% of immediate-
release opioids prescriptions  and an even smaller proportion of extended or long acting opioid 
prescriptions. Yet, guidelines for emergency physicians have garnered the  most attention.” 53 
In reviewing the data source however, this statistic was gained from a source utilizing a projected 
study which was based on insurance claims.  A common characteristic of patients exhibiting 
drug seeking behavior is that their method of payment is often cash or through a government 
assistance program such as Medicare or Medicaid therefore the statistic cited may be 
questionable and need further verification.   
This is supported by Paulozzi et al who stated that it can be difficult to obtain data 
regarding the extent to which prescriptions are originating from ED’s.  However, in 2009, ED 
physicians placed third in opioid prescriptions for two age groups and fourth in a separate age 
group.  It was estimated in their study that 12% of the total prescriptions written for those age 
groups were initiated by ED physicians.
54
   
 Legislation for Deterrence of Prescription Opioid Abuse.  In June of 2011, the state of 
Florida enacted legislation known as the “Anti-Pill Mill” bill (HB 7095).  This legislation 
provides a comprehensive strategy to deter the prescription opioid abuse epidemic through 
enhanced administrative penalties and criminal laws targeting physicians and pain clinics 
engaging in trafficking of prescription opioids.  The bill also establishes prescribing guidelines, 
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invokes pain management physician registration with the DOH and prohibits dispensing of 
controlled substances.   The bill also addresses oversight of distribution points and lessens the 
time allowed to enter data into the PDMP. 
55 As the amount of available opioids are diminished 
by the closure of local “pill mills”, ED physicians must be prepared for increased volumes of 
patients exhibiting drug seeking behavior .   Also, law enforcement agencies are reporting rises 
in heroin abuse subsequent to steps taken to reduce the number of pill mills and overprescribing 
practitioners. 
56 
The Changing Economic and Healthcare Climates 
 Paradigm Shift to Patient Satisfaction Based Reimbursement.  In 2002, CMS 
partnered with the Agency for Healthcare Research and Quality (AHRQ) to develop a patient 
survey to address specific areas of quality improvement.
57
 The survey is referred to as Hospital 
Consumer Assessment of Healthcare Providers and Systems (HCAHPS) and, in May 2005, the 
survey received an endorsement from the National Quality Forum (NQF), which  represents a 
large number of health related providers and service organizations. The survey was formally 
approved in December 2005 and implemented in October 2006.   
 The Deficit Reduction Act of 2005 created additional incentives to implement HCAHPS 
as, commencing in July 2007, hospitals receiving funds as part of the Inpatient Prospective 
Payment System (IPPS) must provide HCAHPS data to receive payment and avoid penalties.  
Per the Patient Protection and Affordable Care Act of 2010, the provision of HCAHPS data is a 
parameter utilized to calculate incentive payments as part of the Hospital Value-Based 
Purchasing program.  As an example, CMS can withhold 30% of the hospital’s incentive monies 
should patient scores be unsatisfactory.”58 
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In October 2012, CMS was to begin reducing the “base operating diagnosis-related 
group” (DRG) payments to hospitals, by 1%.  The monies represented by this percentage were to 
be used to create what is estimated as an $850 million incentive fund. 
59
   Monies would be 
distributed based upon performance of certain quality measures such as patient responses to the 
HCAHPS survey.  The amount actually distributed to the hospitals varies and is based on 
performance measures.  Amounts are expected to increase and the possibility exists that other 
reimbursing agencies from the private sector will likely follow suit. Value-based purchasing is a 
requirement of the new Patient Protection and Affordable Care Act which was part of the 
healthcare reform legislation in 2010.    
A number of vendors are authorized to distribute the HCAHPS survey including Press 
Ganey Associates.  Up until the development of the HCAHPS survey, Press Ganey had been 
conducting patient satisfaction surveys for approximately 40% of the hospitals in the US.  
Though utilizing its own patient satisfaction based instrument in the past, it will now be serving 
as a vendor for the HCAHPS survey.   
The purpose of the HCAHPS survey is to allow patients to rate their inpatient experience 
and perceived level of care.  As HCAHPS will be the instrument of choice by CMS, all results 
will be located on a public domain and visible by internet at www.hospitalcompare.hhs.gov.    
Data from the site can be used for a number of quality improvement activities including 
evaluation of hospitals, enhancement of patient decision making,  and to serve as an incentive for 
hospitals to deliver what patients report as high quality care.
60 
The appropriateness of patient surveys as a means of assessing the quality of medical care 
offered by a physician is a highly controversial topic.  The following are excerpts taken from the 
literature and physician based websites regarding this subject: 
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1. “Doctors who refuse to prescribe opioids to certain patients out of concern about abuse 
 are likely to get a poor rating from those patients.”32 
2.
 “By creating a monetary incentive to increase patient satisfaction, the government is not 
 only increasing its expenses but promoting a metric that significantly increases death 
 rates,” says William P. Sullivan, an emergency room doctor in Spring Valley, Ill.61 
3.
 “Ask most emergency physicians and they will tell you that satisfaction surveys pressure 
 physicians to overprescribe multiple medications, including antibiotics and opiates.”62 
4. “These drugs are highly addictive, even in short-term use. These drugs have been 
 associated with death, even in therapeutic dosing. These drugs, when accidentally 
 ingested by children, are fatal. As doctors, we must stop fearing patient-satisfaction 
 surveys and talk honestly to our patients about pain. It may take an extra few minutes, but 
 it will save lives.” 63 
5. “Some doctors say the many pressures they face create other incentives to quickly 
 prescribe remedies for patients complaining of severe pain. For example, doctors are 
 often rated by their hospitals with patient-satisfaction surveys for how they treat pain. 
 “You can be faulted for not treating a patient’s pain — it’s considered the ‘fifth vital 
 sign.
64
 
As noted by ED physicians, there are strong concerns regarding the inclusion of patient 
satisfaction scores as part of the reimbursement processes.  Concerns have been expressed in the 
past regarding the accuracy of survey instruments such as those utilized by Press Ganey.    The 
following is an excerpt from an article that ran in Forbes magazine in January 2013.  The article 
was an investigative piece on the value of patient satisfaction scores and physician response.   
According to the article, these are the words of an ED doctor: 
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The doctor there responded by administering Dilaudid, a powerful intramuscular narcotic 
typically reserved for cancer-related pain. Why, his nurse queried, was he killing a flea 
with a sledgehammer? Afraid of malpractice? No, the doc replied, Press Ganey. ‘My 
scores last month were low.
 61 
According to Dr. Brenda Sirovich,  
Our health care system already suffers from a ‘more is always better’ fallacy. Practicing 
physicians have learned–from reimbursement systems, the medical liability environment 
and clinical performance scorekeepers–that they will be rewarded for excess and 
penalized if they risk not doing enough.  An overreliance on patient surveys, she says, 
only inflames the problem of overtreatment.
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CMS has engaged researchers to identifying any potential bias in the HCAHPS survey and is 
reportedly considering the use of conversion factors to normalize the data where biases have 
been identified. 
 Emergency department physicians question the validity of utilizing patient satisfaction 
scores as a means of for evaluating medical care and ultimately administrative decisions.  The 
bias aside, the question arising in the literature is whether they should be utilized as a metric for 
the quality of care delivered.  Among the concerns are whether patients have the capacity and 
knowledge base to best evaluate their actual level of delivered medical care.  Also, should a 
patient make a recommendation that is based on a medical procedure, could the hospital ethically 
or administratively be in a position to make changes based upon patient recommendations.   In 
addition to the concerns regarding bias, does the survey instrument allow for variables with the 
capability of skewing the data.  Also, ED physicians treat patients with substance abuse issues 
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who would not be satisfied should the ED physician refuse to prescribe a drug of potential abuse 
such as an opioid.  There are other considerations such as patients with mental illness or without 
the physical capabilities to respond to the surveys.
 65
  
 According to Dr. Joshua Fenton, higher patient satisfaction scores are associated with 
increased mortality, higher inpatient use, as well as increased healthcare and prescription drug 
expenditures.
66
    
 Customer satisfaction is not a new concept.  Corporate and service based industries rely 
on client satisfaction surveys however, consumers for those industries are in a better position to 
judge the quality of their experience.  Emergency Physician Monthly posted survey results which 
revealed that 16% of their respondents stated that low satisfaction scores had threatened their 
employment.  Twenty seven percent cited that their income was linked to patient satisfaction 
scores.
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 Recent research has determined inaccuracies in the methodology utilized by Press 
Ganey's measurement and reporting.  Sullivan and DeLucia report that the firm uses comparative 
data based upon small sample sizes thereby creating a large margin of error.  They also found 
that the firm often provides comparative data about hospital departments and individual 
physicians based on a smaller sample size that may create an unacceptably large margin of error.
 
67
   A possible bias can also be identified with ED patients and their wait times.  Scores might be 
much lower for that population as opposed to the ED patient that’s admitted, who received the 
highest level of care, but does not receive the survey.  
 Another metric now considered by CMS is that of “door to discharge” times.68,69 
Emergency department volumes continue to rise and overcrowding has been the topic of 
numerous studies and litigation.  Emergency department physicians  must be attentive to this 
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aspect of care due to potential loss of reimbursement but also due to the potential revenue lost 
from patients leaving prior to being seen.
70,71
 
Electronic Medical Records.   A federal investment of $30 billion was established for 
the purpose of moving hospitals toward implementation of electronic medical records (EMR).   
The use of EMR is now a federal mandate but exacts a toll on ED physicians with regard to time 
spent with patients.   According to a report published in May 2013, ED physicians spend less 
time with patients than they do entering data into the EMR.  The report cited inefficiency in data 
entry processes and noted that improvement would permit greater time with patient, improve 
efficiency  and increase hospital revenue.
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 Economic Impact from Oxycodone.   Of the prescription opioids most commonly 
abused and drawing the most attention by ED physicians was the drug OxyContin.  The following 
highlights a number of the economic and clinical factors impacting ED physicians:
74
  
1. The drug was approved by the FDA in 1995 which coincided with the APS initiative of 
the “fifth vital sign.”     
2. The active ingredient in OxyContin tablets is oxycodone which is also mixed with 
acetaminophen and sold as Percocet.  These are among the most commonly reported 
drugs of abuse seen in the ED.  
3. Although the label warns users against this practice, ED’s manage patients who have 
insufflated the drug. 
4. OxyContin sales escalated rapid in 1996.  In 2001 and 2002, sales exceed $1 billion. 
5. Reports of abuse and diversion began in 2000 appearing first in rural areas. 
6. One report noted ED visits rising as early as 1999. 
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Impact of the “Great Recession” on ED Patient Volume.  Ongoing changes in both 
healthcare and economic climates, have contributed to a significant increase in ED patient visits
 
 
including those exhibiting drug seeking behavior.
 1
 The impact of a recession is most often felt 
by disadvantaged groups such as those with lower incomes. An additional sequelae from 
recessional times is the risk of increased mental health issues.  The World Health Organization 
stresses that “social capital and welfare protection” are critical to healthy lifestyles.  Therefore 
the financial stress to those already unemployed, with higher debt, poorly educated and in 
poverty will be at risk for increased needs to seek out medical care.75    
In 2010, the Journal of the American Medical Association (JAMA) released a report, 
based on ED visit rates from 1997 – 2007, which revealed an increase being twice that of the US 
population growth rate.
76
   Patients receiving Medicaid represented a higher percentage of that 
increase.  A possible explanation would be that patients on Medicaid are experiencing greater 
difficulties in establishing a relationship with a primary care physician.
77,78
  
Subsequent to the JAMA study, ACEP conducted a survey among their ED physicians 
regarding their perspectives on increased ED volumes and the results were released in April 
2011.  The report indicated that  >  80% of responding ED physicians noted that patient volumes 
were increasing and of those,  > 90% felt increases should continue to be expected.
79
 In 2009, 
ED visits increased to 136 million, from 124 million in 2008, representing an approximate 10% 
increase which is the greatest single year increase on record. 
The “Great Recession” of 2008 coincided with the time of these studies and, though 
affecting healthcare costs, one of the most serious sequelae was the loss of employment 
ultimately leading to a loss in employer paid private insurance. Of the 136 million ED visits in 
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2009, the number of uninsured patients had risen from 15.4% to 19% and the percentage of 
privately insured patients had dropped from 41.9% to 39%.
1
    
With state budgets having to overcome a $160 billion deficit, and federal government 
stimulus funds will only offset $60 billion this year, growing pressures are being exerted to 
reduce funding for Medicaid.
80
   
Due to Medicaid’s poor reimbursement, private physicians may limit the number of 
Medicaid patients in their practice or refuse to participate as a provider altogether.
81 
 This excerpt 
from a pain management physician’s internet site: 
And I don’t accept Medicaid or Medicare as payment for treatment. I feel guilty for 
admitting that, but I don’t think I could stay in practice if I accepted what these 
government programs pay for treatment. When I first opened my own office in 2010, I 
saw a handful of these patients for free, since trying to file and going through the 
necessary red tape isn’t worth the pittance these programs pay for an office visit. 82 
This serves to increase the overall Medicaid patient volume in the ED but also may be a factor in 
the increased volume of these patients who are exhibiting drug seeking behavior.  According to 
the CDC, Medicaid recipients are prescribed opioids at twice the rate of non-Medicaid 
recipients
83
 and are six times more like to overdose on these analgesics.  A study conducted in 
Washington State study reported that 45% of the fatalities from prescription opioid overdose 
were Medicaid recipients.
84,85 
 
The sequelae of increased ED patient volumes, is decreased resources to the patient 
specifically time spent with the ED physician.
1
  Dr. Anna Lembke, a psychiatrist  from Stanford 
University writes, 
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Time spent with each individual patient is medicine’s least valued  commodity from a 
financial reimbursement perspective. That’s  especially true in emergency department 
settings, where physicians are often evaluated on the numbers of patients seen, rather 
than the amount of time they spend with each one… Currently, it is faster and pays better 
to diagnose pain and prescribe an opioid than to diagnose and treat addiction. Busy 
emergency physicians who would like to refer patients with addiction for appropriate 
treatment have few resources to call on.
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Reduction of Resources.  According to a 2010 report, the number of ED’s in the United 
States has decreased to 3925 in 2007 from 4114 in 1997.  Due to EMTALA, ED physicians work 
under a federal mandate to provide care for all individuals seeking emergency medical care, 
regardless of their financial status. However, the result is the ED physicians represent the least 
compensated of all disciplines with approximately half of the services provided not receiving 
proper compensation.
86
 According to CMS, less than 3% of the $2.1 trillion spent on healthcare 
will go to emergency medicine providers caring for 120 million annually. Decreased 
reimbursement and growing lack of compensation are resulting in the closures of emergency 
departments nationwide ultimately threatening public health as a whole.   
 The ACEP released a report in 2011 regarding a survey conducted among their members. 
Approximately half of those responding stated that the fear of litigation was considered to be the 
largest obstacle to decreasing ED costs.  Dr. Sandra Schneider, president of ACEP at the time of 
the survey, was quoted as saying: 
  Emergency medicine provides lifesaving and critical care to millions of patients each 
 year and yet only represents 2 percent of the  nation’s health care expenditures. 
34 
 
 Emergency departments need more resources, not fewer, and medical liability reform 
 would help reduce  overall costs by reducing the need for defensive medicine.
 86 
Hospital Administration. Emergency department physicians have an ethical obligation 
to advocate for the safety and overall health of their patients yet may feel pressure from hospital 
administrations with regard to daily practices including the prescribing of opioids.
 5,32 
  The role 
of ED physicians is unique in that unlike the private practitioner, who may elect the patients to 
be seen in their practice, they serve under a federal mandate to provide services to all patients.  
The ED patient population is often among the most “vulnerable”, may be physically and/or 
mentally disabled, may be uninsured, and may present as suffering from a catastrophic illness or 
trauma related injury.  The need to advocate for the best interest of the patient may place the ED 
physician in a precarious position with hospital administrative staff. 
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Emergency department physicians should have the privilege of due process rights if they 
are going to be in a position to advocate for their patients.   Due process should insure ED 
physicians that they will not lose staff privileges without the benefit of a fair hearing.
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 A 1998 survey of ED physicians revealed that many of the respondents had been 
threatened by hospital administrations subsequent to questioning staff regarding quality 
assurance concerns and / or financial issues.
89
  The timing of the survey coincided with the 
initiation of pain as the “fifth vital sign” and the beginning of significant rises in ED patient 
volumes.
76
  
 Depending on the hospital, admissions may generate more revenue than the ED visit in 
and by itself thereby potentially placing on the ED physician to acquiesce the administration’s 
desire for greater admissions.  According to an article in the New York Times,  
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two ED physicians, employed by an ED management group, were interviewed and related that  
“hospital administrators created targets for how many patients they should admit.”90   The 
rationale was that more admissions generated greater revenue for the hospital.
91
   One of the ED 
physicians related receiving telephone calls questioning why he had not admitted an elderly 
patient when the hospitalization could easily have been explained.  “The pressure to admit was 
so high” and subsequently the ED physician left the hospital.  A second ED physician 
approached administration with concerns that the nurse to patient ratios were too high and 
causing an unsafe environment.  In this case, an executive from the ED management group 
warned him to “back off.”  He was later fired, along with his wife who worked at the same 
hospital.  Both the physician and his wife are pursuing a legal course of action.  
 A great number of ED physicians are employed by management groups rather than being 
individually paid by the hospital itself.  These groups, referred to as a contract management 
groups (CMG) are primarily for-profit corporations which may relate in additional stress being 
perceived by the ED physicians with regard to finances and generation of revenue.  CMG’s often 
report to shareholders as opposed to the ED physician whose obligation is to the patient.  
 A nationwide survey completed in 2012
88 
questioned ED physicians regarding their 
concerns regarding this topic.  As indicated in the 1998 survey, due process and the ability to 
voice concerns without fear of repercussion were still of concern to the ED physician.   
Additional concerns were that of charging issues such as admissions and utilization of specific 
tests.  Although still perceived as a pressure to admit, there were also opinions offered to the 
opposite specifically a pressure to discharge.  With recent healthcare changes, a readmission 
within 30 days can be viewed as a quality measure violation and therefore denial of 
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reimbursement.  Specific references were made as to pressures of admission or discharge when 
dealing with Medicaid patients.  
 CMG’s rely on establishing and maintaining a good rapport with hospital administration 
in order to insure continuance of contracts.
92
 Less than half of the ED physicians reported that 
they would feel comfortable approaching administration with concerns.   
Management of Patients Exhibiting Drug Seeking Behavior 
Training in Management of Prescription Opioid Abuse.  When reviewing the public 
health response to past epidemics, training and education has been viewed as an integral 
component to deterrence.  As an example, in response to the Human Immunodeficiency Virus 
(HIV) epidemic, the Florida Omnibus Acquired Immunodeficiency Syndrome (AIDS) Act of 
1988 was passed and includes the requirement that all healthcare professionals enroll in an HIV 
education course.
93
   This education includes the identification of “high risk” populations, patient 
signs and symptoms associated with the virus, identification methodologies, including the use of 
previous medical records, and appropriateness of pharmacologic therapy and referral.   
 Though prescription opioid abuse has been declared an “epidemic”, surveys of health 
care professionals and medical schools reveal significant gaps in education and training on pain 
management, substance abuse, and safe prescribing practices.
94
   According to the 2013 White 
House Policy on Drug Control, healthcare prescribers and dispensers receive “little training” on 
the recognition and appropriate prescribing of opioids.
95 
  A 2000 survey of medical school 
residency programs revealed that only 56% required education in substance abuse disorders.
96
 In 
2008, follow up surveys showed “some progress” in the medical school, residency and post-
residency education but no standardization has taken place among these areas.
97
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 In an article reported by Time Magazine, two ED physicians spoke on the topic of 
prescription opioid abuse as it relates to emergency medicine.  The following describes their 
training with regard to prescribing of opioids: 
Next, medical students and trainees were instructed that patients could never become 
dependent on narcotics if prescribed for legitimate pain. (We both remember being taught 
this myth.) Last, opioid pain medications like oxycodone (the active ingredient in 
Percocet) and hydrocodone (the active ingredient in Vicodin and Lortabs) were framed as 
safer alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, 
naproxen and Vioxx that could trigger peptic ulcers or cardiac conditions.
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Inherently, all opioids have the potential for abuse and gaps in education, such as listed above, 
may facilitate improper prescribing of opioids and potential for abuse.  In the 2011 White House 
Policy, issued by the ONDCP, titled “Epidemic: Responding To America’s Prescription Drug 
Abuse Crisis”,99  the following recommendations have been made with regard to future education 
on prescription opioid abuse: 
1. Amend a Federal law which would require practitioners with DEA licenses to receive 
 CME on “responsible opioid prescribing practices.”  Included in the training would be 
 special topics on assessment and addressing the signs of prescription opioid abuse.  
2. Drug manufacturers would be required to participate in REMS training which provides 
 education initiatives for training prescribers on appropriate use of opioid analgesics.   
3. Federal agencies will provide CME for their prescribers and allied healthcare providers. 
4. Establish working relationships with medical schools and other healthcare schools to 
 develop curricula and CME that would include instruction on recognition and 
 management of patients exhibiting drug seeking behavior.  In addition, these educational 
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 entities could be used for community education and dissemination of educational 
 materials.   
Identification of Prescription Opioid Abuse.   Several tools are available to ED 
physicians for the identification of prescription opioid abuse including drug testing, PDMP’s and 
targeted history screening.
100,101,102    
The Current Opioid Misuse Measure (COMM) was initiated 
to assist clinicians in identifying potential prescription opioid abuse.  The COMM utilizes self-
reporting of  present risk for “aberrant medication-related behavior” among patients being treated 
for chronic pain. The COMM varies from other tools in that it was not designed to identify the 
specific characteristics that many recognize as possibly leading to abuse but rather assists in the 
identification of patients who may be currently misusing opioids.   
The two most common used media by ED physicians for performing drug screening are 
urine or blood.  These tests are relatively inexpensive however the traditional Substance Abuse 
and Mental Health Services Administration (SAMHSA)
103
 test, which includes screening for 
marijuana, cocaine, amphetamines, PCP and opiates, may not include synthetic opioids.  Pilot 
studies indicated that a significant percentage of the ED physicians’ hospitals did not screen for 
the synthetic opioids thereby requiring the samples to be sent to the hospital laboratory or an 
outside facility.  The latter option is not practical logistically unless the patient was being 
admitted.  The former option was perceived by ED physicians as possible but did contribute to 
time delays and increased cost to the patient. 
In the 2011 Prescription Drug Abuse Prevention Plan, the use of PDMP’s was 
recommended 
104  
by the Office of National Drug Control Policy (ONDCP).
105  PDMP’s are 
“substantially underutilized” in our efforts to reduce the prescription opioid abuse epidemic.106  
Key factors for failure to use this resource include non-standardization of information collected 
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by individual state PDMPs, concerns regarding safety of data storage and accessibility, the 
methodology for examining the data, variance in reports generated and a lack of consistency with 
regard to the availability of the data. 
 Emergency department physicians have cited that failure to utilize prescription opioid 
abuse identification tools such as laboratory drug screening and PDMP database queries is often 
attributed to economic factors and possible civil liability.
107,108
  Budgetary limitations , staff 
allocation and increased patient volumes decrease the time available for ED physicians to query 
the PDMP or await backlogged laboratory results.  Any factors that would increase “door to 
discharge” time serve to decrease patient satisfaction thereby initiating a potential conflict with 
administration due to possible reimbursement ramifications.  The ED physician must weigh these 
factors against the benefit of “establishing patterns of abuse” and whether treatment would be 
altered in any way based upon this information. 
The fear of litigation is a concern as legal cases are well documented for instances where 
physicians failed to prescribe adequate pain medication
109
 as well as prescribing without counsel 
on adverse effects.
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Reasons cited in the pilot studies by this researcher include simple lack of knowledge as to how 
to access the database and administrative details viewed as cumbersome (e.g. frequent switching 
of passwords, mandatory tutorial). 
Opioid Prescribing Practices.  “Emergency department physicians have access to a 
number of sources who have published, or made public, evidence-based recommendations with 
regard to responsible opioid prescribing practices.
5,46 
 The ONDCP as well as numerous states 
have published recommendations for opioid prescribing to chronic and acute pain patients.  A 
duty to act is emphasized  in the ethical treatment of pain while respecting the potential that 
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opioid analgesics possess with regard to possible dependency and addiction issues.
16
  When 
matched with identification tools such as utilization of PDMP’s and laboratory testing, in 
addition to administrative protocols for management and referral, prescribing practices served as 
the foundation for prescription opioid protocols.  The consensus among sources focused on the 
following:   
1. Consideration of short-acting, as opposed to long-acting  opioid analgesics for treatment 
of pain. 
2. Consider lowered doses depending upon body weight and other clinical indicators. 
3. Limit the supply.  Some prescribing guidelines adhere to no more than 72 hours.  
4. Screen for possible abuse utilizing EMR and targeted histories. 
5. Query the state PMDP. 
6. Utilize non-opioid and / or non-pharmacologic therapies. 
7. Avoid prescribing opioid to patients already prescribed long acting opioids and / 
benzodiazepines to prevent potential drug interaction and CNS depression.  
8. Verify with treating physician the validity of claims that prescription is lost / stolen.  If 
replacement is deemed warranted, a limited supply is advisable. 
9. Provide information regarding the risk of impairment, overdose and potential long term 
effects of dependency and addiction.  
Physicians stress taking the time to discuss the medications with the patient.  Two excerpts from  
the literature are listed below: 
1. “Time spent with each individual patient is medicine’s least valued commodity from a 
financial reimbursement perspective. That’s especially true in emergency department 
settings, where physicians are often evaluated on the numbers of patients seen, rather 
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than the amount of time they spend with each one… Currently, it is faster and pays better 
to diagnose pain and prescribe an opioid than to diagnose and treat addiction. Busy 
emergency physicians who would like to refer patients with addiction for appropriate 
treatment have few resources to call on.”32 
2.  “These drugs are highly addictive, even in short-term use. These drugs have been 
associated with death, even in therapeutic dosing. These drugs, when accidentally 
ingested by children, are fatal.” As doctors, we must stop fearing patient-satisfaction 
surveys and talk honestly to our patients about pain. It may take an extra few minutes, but 
it will save lives.”98 
Summary 
Subsequent to a literature search of peer reviewed articles, periodicals and physician 
based media sites, it was confirmed that a significant information gap exists with regard to the 
perceptions of ED physicians and the economic and regulatory factors impacting their 
management of patients exhibiting drug seeking behavior.   
 As a further result, the content of survey questions has been validated and hypotheses 
formed for the pursuit of future research. 
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CHAPTER THREE: METHODOLOGY 
Design 
The research design selected for this study was a descriptive, cross-sectional, 
epidemiological model utilizing a survey tool to assess the current opinions of ED physicians 
with regard to the impact of economic and regulatory factors on their management of patients 
who are exhibiting “drug seeking” behavior.   This study design was not constructed for the 
purpose of determining causation but to determine trends and commonalities observed through 
the participant’s personal experience and training.  
Sample 
A convenience sample of ED physicians was asked to complete the online survey 
instrument.  A power analysis revealed the need for at least one hundred (100) ED physicians to 
participate. The inclusion criteria specified that participants could be any physician serving in the 
capacity of an ED physician within the United States.  Exclusion criteria specified that 
participation could not occur if you were not a physician serving in the capacity of an ED 
physician within the United States.  
Instrument  
This study utilized a survey tool which was developed and used in a pilot survey 
(February 2012).  The questions were revised and tested for content validity by a group of 
experts in emergency medicine and education.  The survey includes a maximum number of thirty 
nine (39) multiple choice questions with an optional essay question at the conclusion allowing 
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for the physician to provide additional comments. Screening questions within the survey 
reinforced inclusion criteria.  
To decrease study limitations, all applicable survey questions included a provision at the 
end of the question which provided an option for the participant to provide an opinion not 
included in the multiple choice options for that particular question.  Provision was also made at 
the conclusion of the survey for participants to add comments not addressed by survey questions. 
The same survey questions will be utilized as the basis of focus group sessions and personal 
interviews for those electing to participate through this option.  The survey questions have 
received IRB approval through the University of South Florida (IRB #9509).   
Procedure 
A research study invitation was distributed to various medical/professional organizations, 
as well as individual clinicians, utilizing both publicly obtained, and personally known, 
email/physical addresses.  Invitations were sent based upon the inclusion criteria and responses 
included in this study were collected over a two-month period.  Any participants electing to 
participate through focus groups or personal interviews were provided with the same questions 
as those taking the online survey and their responses were merged with those entered through the 
online survey tool.   
 Data were downloaded from the online survey tool website in an Excel spreadsheet 
format.  No identifying information was obtained and data was maintained in password protected 
computers throughout the research project.  
Data Analysis 
The data were analyzed using SPSS analytical software.  Demographics of interest 
included age, length of time practicing as an ED physician, board certification status, venue and 
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description of practice.   For specified hypotheses, the sample was divided into physicians 
working nonprofit versus for-profit hospitals.  
 To evaluate trends and overall responses, descriptive statistics (e.g. averages, standard 
deviations, frequencies and confidence intervals) were used in conjunction with all survey 
questions.   
 To establish relationships and possible correlations of the sample and sub-samples (i.e. 
physicians employed by for-profit versus nonprofit organizations). Independent t-tests were 
utilized.  A critical alpha level of .05 was used as a means to reject, or fail to reject, the specified 
hypotheses.   
 For questions using a Likert type scale, Spearmen’s correlation was utilized to measure 
associations between the ranked variables.   A range of -1 to +1 was used to determine strength 
of correlation and the actual value would be subjected to significance testing to determine 
probability of chance.  
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CHAPTER FOUR – RESULTS 
Sample Demographics  
 The sample for this study is comprised of 141 currently practicing ED physicians, MD’s 
and DO’s, from 31 – 70 years of age as depicted in Figure 1: Age of Participants.  There is a 
wide range among the participants in years of ED experience with 40% having started in 1995 or 
before to 9% with less than 2 years of experience (Figure 2) The majority of the participants 
(88%) were boarded in emergency medicine, but other boards were listed as well including 
internal medicine, pulmonology, family medicine and pediatrics.  The participants see adult, 
pediatric, or a combination of these patients and are fairly well distributed between for-profit and 
nonprofit hospitals. 
Management Practices 
 Training.  As a means of eliciting information regarding the physicians’ recognition and 
management of patients exhibiting drug seeking behavior, the participant were presented with 
two questions.  The first asked them to describe characteristics of drug seeking behavior based 
upon their clinical experience.(Figure 3)  The second asked them to specify the drugs most 
commonly requested by patients exhibiting drug seeking behavior  (Figure 4).  While nearly half 
(47%) of the participants have received Continuing Medical Education (CME)  in the last 3 years 
on recognition and management of prescription opioid abuse, nearly a quarter (22%) have had no 
training at all on this topic (Figure 5). When asked if ED physicians “should receive some type 
of specialized CME to assist them with recognition and management of prescription opioid 
abuse”, 84% of the participants responded affirmatively (Figure 6).  Hypothesis five stated ‘Less 
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than 50% of ED physicians have received formal training through either continuing medical 
education or medical school/post-graduate curricula, on recognition and management of 
prescription opioid abuse.’ This hypothesis is not supported as 57.1% of the participants had 
received training on this topic.  
 Opioid Abuse Identification.  The participants were asked to rate their use of opioid 
abuse identification methods.  Five specific methods were presented to the participants:  physical 
examination, history, use of EHR, drug screening and query of the state prescription drug 
monitoring program (PDMP) database.   Survey questions were designed using a four column 
Likert type scale.  Options included “always”, “frequently”, “occasionally”, and “never.”  Few 
respondents (9%) “always” utilized drug screens as part of their identification methods for 
potential opioid abuse.  Of the remaining participants, 22% used it frequently, 46% used it 
occasionally and 23% never utilized this method (Figure 7).  Only 25% of the respondents cited 
that their ED had the ability to screen for synthetic opioids.  Twenty-nine percent (29%) stated 
that testing for synthetic opioids required submission to the hospital laboratory and 33% reported 
that screening for synthetic opioids had to be sent to an outside laboratory (Figure 8).  
 The following correlations were observed with regard to use of opioid identification 
methodologies.  A low, positive correlation exists between the use of drug screens with the 
ability to perform screens for synthetic opioids in the ED (as opposed to sending samples to the 
hospital or outside laboratories). (r = 0.393, P, 0.001) (Figure 9).  A low, negative correlation 
exists between the physician’s willingness to use drug screens and their knowledge of using the 
PDMP (r = -0.186, P=0.031).   A low, positive correlation was found between the physician 
performing a physical exam as a means of determining opioid abuse and the physician who 
avoids using the PDMP for fear of decreased patient satisfaction if the PDMP shows a positive 
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result for doctor shopping.  (r = 0.179, P=0.039).   Additionally, a low, negative correlation 
exists between the physician performing a physical examination to detect opioid abuse and the 
physician’s knowledge of accessing the PDMP.   (r = -0.174, P=0.045).   
 Regarding participant utilization of the PDMP, 18% always used this method as a means 
of identifying potential opioid abuse, 33% used it frequently, 26% occasionally and 23% never 
used this method. Of those querying the PDMP, 68% reported that the database had identified 
patients as “doctor shopping.”  As a note, 23% of the participants indicated that they are not 
registered with the database and as such, could be among those stating they never used the 
PDMP for identification (Figure 10).  Respondents agreed that certain factors would discourage 
them from using the PDMP including being “too busy” (74%), query process is too time 
consuming (76%), and the risk of patient satisfaction scores being negatively affected should 
opioids be refused due to database findings (41%).  Civil liability was only a concern among 
(14%) of the participants.  Lack of awareness on how to access the database was cited by 36% of 
the participants, respondents were unaware of how to access the database (Figure 11).  The 
participants were also asked to comment on factors which might encourage them to use the 
PDMP.  Ninety-two percent indicated that signs of drug seeking behavior would encourage use, 
80% felt that a PDMP query indicating “doctor shopping” would support their refusal to 
prescribe opioids and the next highest response was a history of past drug abuse (72%).  
Additional lesser cited reasons are listed. (Figure 12).   
 Opioid Prescribing Practices.  When asked about the participant’s opioid prescribing 
practices, the obtaining of the patient’s history, a physical examination and review of past 
medical records were reported as always being conducted.  Only 12% of the participants always 
used drug screens and the PDMP respectively prior to prescribing opioids. The highest 
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percentage (60%) of opinions, with regard to utilizing drug screens prior to prescribing, was 
noted as falling under the “occasionally” column (Figure 13). This was confirmed by a stand-
alone second survey question which asked the participants if drug screens were conducted prior 
to prescribing opioids.  Forty-nine percent of the participants responded that they would 
“occasionally” conduct the drug screens prior to prescribing opioids (Figure 14).  
When asked what would discourage the respondent from performing a drug screen prior 
to prescribing opioids, 87% cited the wait time for laboratory reports would delay discharge 
(Figure 15).  “Door to discharge” times are strong considerations to ED physicians due to 
economic factors such as administrative expectations to meet higher patient volumes and 
reimbursement entities such as Centers for Medicare &Medicaid Services (CMS) using this as a 
financial metric.  Additional reasons cited by the participants as discouraging use included the 
perception that cost outweighs benefit (77%) and that treatment is not affected by laboratory 
results (77%).  Returning back to the data provided by the participants, which related that more 
than half of the drug screens would have to be submitted to either the hospital laboratory or an 
outside laboratory, this could influence the reluctance to utilize drug screening more frequently.  
 When drug screens are conducted, the participants were asked to provide their opinions 
as to any trends which have been observed when reviewing the laboratory results from 
specimens belonging to patients exhibiting drug seeking behavior.  The most common finding 
was the presence of illicit drugs.  Sixty percent of the participants found this to be frequently 
reported.  Drugs not prescribed to the patient was noted by 53% of the respondents (Figure 16). 
  When asked about hospital administration’s position regarding use of the PDMP prior to 
prescribing opioids and/or other controlled substances, 54% of the respondents indicated that 
their hospital administration supported use of the PDMP prior to prescribe opioids, 2% stated 
49 
 
that use of the PDMP was discouraged and approximately 56% of the responses reflected either a 
“neutral” or “unknown” position from their respective hospital administrations (Figure 17). 
 It was hypothesized that there would not be a significant difference between the opinions 
of  ED physicians working in for-profit hospitals, versus nonprofit hospitals, with regard to their 
perceptions of economic pressures from administration to prescribe opioids. Independent t-test 
results demonstrated  this as no p-value results of  less than 0.05. 
 
 
Regulatory and Legal Actions 
 Physicians were asked to respond to the following statement:  "Patients in our culture 
view drugs as a solution therefore you risk a patient complaint if you don't provide a script on 
discharge."  Ninety percent (90%) of the physicians agreed with the statement and 50% of those 
indicated that they strongly agreed (Figure 18).  The participants were asked to rate the 
significance of their concerns should they query the PDMP and be presented with a response 
indicating evidence that the patient queried was “doctor shopping.”  Specifically this question 
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addresses perception of statutory, regulatory, civil and administrative guidelines as to the course 
of action subsequent to receiving the query response.  Eighty-six percent of respondents 
indicated a concern that hospitals do not provide physicians with a course of action, 82% were 
concerned that the Board of Medicine has not provided clarity on a course of action, 73% 
indicated a concern that statutes were not clear as a course of action, 60% were concerned that 
notifying law enforcement would result in a HIPAA violation, and 41% are concerned regarding 
civil liability for failure to report (Figure 19). 
Participants were asked to rate their concerns regarding perceived “pressure to prescribe 
opioids, even in the presence of ‘drug seeking’ behavior,” in order to avoid regulatory, civil and 
administrative scenarios. (Figure 20)  Forty-six percent agreed that potential Board of Medicine 
complaints regarding adequate pain management would constitute a pressure to prescribe; 26% 
felt a pressure to prescribe due to potential civil liability (e.g. withdrawal, over/under 
prescribing); 72% felt pressured to prescribe in order to avoid administrative complaints from 
patients stating their pain was inadequately treated;  57% felt pressured to prescribe opioids due 
to potential negative impact on Joint Commission surveys; and 46% felt the pressure to prescribe 
to avoid decreased patient satisfaction scores and their direct relevance to reimbursement.  
Twenty-three percent of the participants stated that they were unconcerned regarding the 
aforementioned scenarios.  When asked if the participant, or one of their colleagues, had been 
criticized by administration for failure to prescribe opioids, 40% answered affirmatively (Figure 
21). 
To determine the prevalence of administrative opioid / controlled substance prescribing 
protocols, the participants were asked about their hospital’s position on this subject.  Seventy-
one percent indicated their hospital does not have an administrative protocol for opioid / 
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controlled substance prescribing by ED physicians, 23% reported that a protocol exists but 
physician use is voluntary,  and 8% reported that ED physicians have a mandatory protocol 
(Figure 22).  When asked about the components of the protocol, the most prominent (72%) 
response by participants was the requirement to prescribe a limited supply of opioids.  Drug 
screening and use of the PDMP were not components. 
The participants were asked to rate their attitudes toward a number of statements 
regarding the development of an administrative prescribing protocol for opioids and controlled 
substances. Respondents indicated that perceptions regarding administrative opioid / controlled 
substance prescribing protocols vary.  Forty-two percent were opposed and 58% were in favor of 
a protocol. The participants were then provided with two statements regarding the possible 
impact on physicians should this protocol be established.  The first statement asked the 
participants to rate their feelings as to whether this protocol would protect them from disciplinary 
actions. Sixty-eight percent responded affirmatively.  They were also provided with a second 
statement which asked if they perceived that such a protocol would limit the professional 
judgment of the physician. Seventy-one percent responded affirmatively (Figure 23). A number 
of respondents indicated affirmative responses to both questions. The statistical inference is such 
that if the first statement is desirable, the second might not be desired.  Percentages did not vary 
greatly indicating preferences for both statements.   
A significant number of ED physicians reported they are treating an increased volume of 
ED patients manifesting ‘drug seeking’ behavior due to economic and regulatory factors .  This 
is supported after an independent t-test showed that a statistically significant number of ED 
physicians feel that ‘less private physicians accepting Medicare/Medicaid’ had an impact on 
rising patient volumes (t=  -3.068, P=0.003).  A statistically significant number of ED physicians 
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attributed  rising volumes to patient awareness that ED’s are obligated to take them as patients. 
(t= -2.329, P=0.021).  
 
Economic Impact  
 With many reimbursing and regulatory agencies utilizing patient satisfaction scores as a 
metric, physicians were asked if they felt patient satisfaction scores were too highly emphasized 
as a means of assessing good patient care.  Responses indicated that 98% of the participants 
agreed with this statement and 78% of those responses indicated “strongly agree.” (Figure 24). 
The participants were asked to indicate their impression of trends in ED patient volumes in the 
last two years.  Ninety-one percent reported a perceived rise in overall volume.  When asked if 
there was also a trend in volume of patients exhibiting drug seeking behavior in that same time 
period, 72% of the respondents indicated that they perceive the volume of patients exhibiting 
drug seeking has also increased (Figure 25).   
Within the last two years, legislation was enacted to reduce the number of “pill mills” in 
numerous states.  The participants were asked, subsequent to their impression that drug seeking 
behavior had increased, if there were any associations which they felt might have contributed to 
this increase.  Eighty three percent noted that the pill mill legislation, and subsequent decreases 
in available opioids, may have contributed.  Ninety percent agreed that patients feel they will not 
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be turned away.  Eighty percent (80%) of the participants attributed some influence to economic 
changes in that less private physicians are participating in Medicaid.  From a regulatory 
standpoint, 70% of the participants indicated greater numbers of physicians are refusing to 
prescribe opioids in general (Figure 26).  With regard to Medicaid, the participants were 
requested to rank any trends in methods of payment noted when treating patients exhibiting drug 
seeking behavior.  Respondents perceived that the number of Medicaid patients exhibiting drug 
seeking behavior is rising.  Thirty six percent of the participants perceive that Medicaid patients 
had increased and 43% indicated that private pay / cash payments have risen in that same two-
year time period (Figure 27). 
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Figure 1: Age of Participants 
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Figure 2: Years of Experience in ED- “When did you begin taking shifts in an ED” 
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Figure 3: Characteristics of Drug Seeking Behavior 
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Figure 4: Commonly Requested Drugs of Abuse 
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Figure 5: Training on Prescription Opioid Abuse 
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Figure 6: Physician Recommendation for CME on Opioid Abuse- physicians “Should 
physicians receive some type of specialized CME to assist them with recognition and 
management of prescription opioid abuse ?” 
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Figure 7: Utilization of Opioid Abuse Identification Methods 
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Figure 8: Drug Screen Availablilty for Opioids 
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Figure 9: Correlation between Drug Testing and Availability 
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Figure 10: Database Queries Indicating Potential “Doctor Shopping” 
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 Figure 11: Factors Discouraging Utilization of PDMP 
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Figure 12: Factors Influencing Utilization of PDMP 
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Figure 13: Opioid Prescribing Practices- Evaluation and assessment performed to guide decision 
to prescribe an opioid as part of the treatment course. 
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Figure 14: Drug Screens Prior to Prescribing Opioids 
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Figure 15: Factors Influencing Non-Utilization of Drug Screens Prior to Prescribing Opioids 
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Figure 16: Laboratory Findings in Patients Exhibiting Drug Seeking Behavior 
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Figure 17: Administrative Position on Utilization of PDMP 
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Figure 18: Cultural Expectations of Pharmacological Agents- "Patients in our culture view drugs 
as a solution therefore you risk a patient complaint if you don't provide a script on discharge."   
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Figure 19: Physician Course of Action When “Doctor Shopping” Indicated 
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Figure 20: Perceived Pressures to Prescribe Opioids 
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Figure 21: Administrative Criticism for Failure to Prescribe Opioids- “Have you, or one of your 
colleagues, been criticized by administration for failure to prescribe opioids?” 
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Figure 22: Administrative Opioid Prescribing Protocols 
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Figure 23: Physician Impact from Administrative Opioid Prescribing Protocols 
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Figure 24: Emphasis on Patient Satisfaction Scores 
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Figure 25: Changes in ED Patient Volume- 2011 to Present 
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Figure 26: Factors Influencing ED Patient Volume 
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Figure 27: Financial Trends in Patients Exhibiting Drug Seeking Behavior 
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CHAPTER FIVE – DISCUSSION 
 This chapter will provide a summary and discussion of the research findings and provide 
recommendations as to potential future research.   
Purpose of the Study 
 This purpose of the study was to elicit the opinions of practicing ED physicians in an 
effort to determine if economic changes and regulatory factors were perceived as impacting 
management of patients exhibiting drug seeking behavior.  The lack of available information, as 
evidenced in a literature search of peer-reviewed works, is the basis for this original research.  
Subsequent to analysis, the data will be used to identify and evaluate factors which may have a 
negative impact on treatment of patients exhibiting drug seeking behavior by ED physicians.   
Demographics of Sample 
 The sample for this study was comprised of 141 currently practicing ED physicians.  
There was a wide range of ages and years of experience among the sample.  This was deemed to 
be of importance to the research as an area of interest was whether newer physicians had 
received training on prescription opioid abuse while either in medical school or in their 
residencies.  The majority of the participants (88%) are boarded in emergency medicine but other 
specialty boards were listed as well.  There was a good distribution of participants with regard to 
their ED practice.  Among the participants were physicians seeing adult patients only, pediatrics 
patients only, or a combination thereof.  Also of interest was whether perceptions would differ 
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between physicians working for nonprofit versus for-profit facilities both of which were 
represented.  
Methodology 
 This study utilized a survey tool which was developed and used in a pilot survey 
(February 2012).  The questions were revised and tested for content validity by a group of 
experts in emergency medicine and education.  The current survey questions were distributed 
and tested for content validity.  The survey includes a maximum number of thirty nine (39) 
multiple choice questions with an optional essay question at the conclusion allowing for the 
physician to provide additional comments. Screening questions within the survey reinforced 
inclusion criteria. 
 To decrease study limitations, all applicable survey questions included a provision at the 
end of the question which provided an option for the participants to provide an opinion not 
included in the multiple choice options for that particular question.  Provision was also made at 
the conclusion of the survey for participants to add comments not addressed by survey questions 
The same survey questions were utilized for those preferring to participate by personal interview 
as opposed to the online option. 
Management of Patients Exhibiting Drug Seeking Behavior  
 Training.  Physicians in the ED are facing a number of unique challenges in the currently 
changing healthcare and economic climates.  Dramatic increases in ED patient volumes have 
been noted nationwide with visits related to prescription opioid abuse and misuse alone having 
increased by 111% between 2004 and 2008.  Participants were asked to describe their level of 
CME training with regard to recognition and management of prescription opioid abuse.  Less 
than half had received formal CME on this topic.  Initiatives by the ONDCP are encouraging 
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medical schools and residency programs to incorporate recognition and management of 
prescription opioid abuse into current curricula.  From a public health standpoint, training is even 
more highly emphasized in the presence of an epidemic.  Education on HIV became mandatory 
subsequent to the declaration of the AIDS epidemic and conversation continues by the ONDCP 
as to mandatory education for providers possessing a DEA license who would be in a position to 
prescribe opioid analgesics.  When asked if the participants felt ED physicians should have some 
type of specialized CME to assist in recognition and management of prescription opioid abuse a 
vast majority (84%) responded affirmatively.  However, what is evidenced through this study is 
that ED physicians would most benefit from education specifically to emergency medicine. 
Unlike the private practitioner, ED physicians do not elect which patients will enter into their 
practice.  They must provide unrestricted access to all persons seeking emergency medical care 
as part of the EMTALA legislation.  Management and care for a patient in the ED will differ 
greatly from the comprehensive care offered by non-ED practitioners.  
 Opioid Abuse Identification.  When the ED physicians were asked to provide 
characteristics which they felt typified the patient exhibiting drug seeking behavior, a number of 
observations were made.  Pain was inconsistent with the patient’s behavior was highly 
mentioned. Patients reporting their pain to be a “10” on a 1 – 10 scale but manifest no grimacing, 
painful expressions, lack of mobility or change in heart and respiratory rates, will cause 
suspicion to many ED physicians in this current time.
110
  This observation could lead back to 
training.  Understanding specific nuances as in vital signs not consistent with pain levels and 
recognition of objective findings consistent with drug abuse is paramount to best practice 
management of patients exhibiting drug seeking behavior in the ED.   
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 Additional observations submitted by the participants as being consistent with  drug 
seeking behavior included abusiveness to staff in their demand for controlled substances.  This 
actually received the highest percentage of responses.  This obviously is of considerable concern 
to ED physicians as they not only have the welfare of the patient as a responsibility but also that 
of the other patients and staff.  It is not uncommon for those exhibiting drug seeking behavior to 
become verbally or even physically abusive to staff when threatened with the potential of not 
receiving their requested drug prescription.  ED physicians will often feel pressured prescribe a 
limited amount of opioids and escalate discharge.
64
  Another characteristic associated with this 
behavior is the actual demand for specific drugs and reported allergies to non-narcotic 
analgesics.  These are significant signs of drug seeking behavior as per our participants.  
Dilaudid (hydromorphone) was noted as being the most requested drug with Oxycontin 
(oxycodone), Percocet (oxycodone with acetaminophen), and Vicodin (hydromorphone with 
acetaminophen) as commonly requested.  Other findings which ED physicians noted to be 
suspicious were patients arriving at the ED on nights and weekends, patients who state their 
prescription for narcotics is “lost” or “stolen”, patients relating their allergic to non-opioid 
analgesics, and abnormal drug screens specifically the presence of illicit drugs, absence of drugs 
stated as prescribed during the history, or presence of a drug not prescribed.  The collection of 
responses as to what typifies drug seeking behavior is supported in the literature as being 
consistent with other research findings. 
 Participants were asked to identify what tools they would utilize to identify potential 
prescription opioid abuse. Performing a history, physical examination and often, review of EMR, 
were the most predominant responses.  Drug screening and utilization of the PDMP are notably 
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good sources of identifying potential prescription opioid abuse however neither were 
predominantly utilized by survey participants.   
 When asked what discouraged participants from utilizing drug screening an interesting 
observation was made.  Only 24% of the hospitals represented by participants in this study have 
the capability of detecting synthetic opioids (e.g. Dilaudid, Oxycontin, Percocet, Vicodin et al) in 
the ED drug screens.  Therefore 76%  must be sent out to the hospital laboratory or, in 33% of 
the cases, sent to an outside facility for testing.  The latter would not be a logistical option unless 
the patient is being admitted.  When asked what observations had been made in reviewing drug 
screens from patients exhibiting drug seeking behavior, 60% of the participants frequently found 
illicit drugs, 54% cited drugs not prescribed to patients as being present, and 24% specified drugs 
prescribed to patient as not being present.   This information, in the hands of an ED physician 
contemplating whether to prescribe an opioid analgesic, could quite possibly impact prescribing 
practices.   
 Another tool available to the ED physician is the PDMP.  When reviewing the states 
represented by participants, it was noted that a functioning PDMP is present in each state.  
Historically, PDMP’s have been reported to be underutilized.104  This research attempted to 
discover the factors which would encourage, or discourage, the ED physician specifically in their 
utilization decision.  The first observation was that approximately one fourth of the participants 
were not registered with the PDMP.  However, of those who are registered and have queried the 
database, approximately 70% reported having received confirmation of activity supportive of 
“doctor shopping.”  This information, as in abnormal laboratory screens, would have bearing on 
prescribing practices with regard to opioid analgesics.  With regard to factors discouraging 
participant usage, the highest concerns noted were both related to time.   The first factor listed 
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indicated that participants were too busy to check the database and the second being the query 
process is time consuming.  Also listed among the concerns was the potential for patient 
satisfaction scores being negatively affected if opioids were refused subsequent to PDMP 
findings.  Civil liability was not recognized as being of concern to participants.  When asked 
what encourages participants to utilize the PDMP,   patient exhibiting drug seeking behavior was 
the most dominant factor with the second being that a PDMP report indicating “doctor shopping” 
would support the ED physician’s refusal to prescribe opioids.  Other factors listed by 
participants were past history of drug abuse, reports of abuse by family and shows due diligence 
in opioid prescribing.   
 A Spearman correlation  was applied regarding use of opioid abuse identification 
methodologies.  Low correlations, both positive and negative respectively, were specific to use 
of drug screens and availability (r = 0.393, P, 0.001), and use of drug screens and physician 
knowledge of how to access the PDMP (r = -0.186, P=0.031).   These results would seem to 
indicate that there is a small correlation between willingness to drug screens and whether the 
screen is available in the ED.  Also observed is the negative correlation between drug screens 
and physician knowledge of how to access the PDMP.  Additional correlations included low 
correlations, negative and positive respectively, specific to performance of physical examination 
and avoidance of PDMP utilization, due to fear of decreased patient satisfaction should PDMP 
results indicate “doctor shopping.” (r = 0.179, P=0.039)  This could suggest that the more a 
physician is willing to perform a physical examination, the less they are willing to utilize the 
PDMP and risk a patient complaint if opioids are refused based upon the PDMP results.  This 
could coincide with the last correlation specifically the performance of physical examination to 
detect opioid abuse as opposed to the physician unaware of how to access the PDMP. (r = -0.174, 
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P=0.045)  Relative frequencies, as discussed in this chapter’s opioid abuse identification section, 
indicate that economic factors play a role in the decision of physicians to utilize prescription 
opioid abuse identification methodologies.   
 
 A t-test indicated no statistical significance between the profit and nonprofit groups when 
asked about the physician’s administration’s position regarding use of the PDMP for opioid 
abuse identification purposes. (t = 1.145, P = .254) 
 Opioid Prescribing Practices.  Participants were specifically asked to comment on their 
opioid prescribing practices.  History, physical examination and review of EMR received the 
highest percentage of responses as “always” being used.  This is consistent with the pattern 
observed when participants were asked about the tools utilized to identify prescription opioid 
abuse.  Also consistent was “occasional” utilization of drug screens but a change was noted with 
regard to the PDMP.  Less participants utilized the PDMP prior to prescribing than as a means of 
identification.  As in the case of why practitioners are not using the PDMP, time factors were 
listed as the most significant deterrent.  Almost 90% of the participants cited that waiting for 
laboratory reports delayed discharge.  Two factors received responses of 80% by participants 
specifically that  cost outweighs the benefit and the treatment is unaffected by laboratory results.  
 When asked to describe their management of non-malignant pain, patients were 
requesting narcotic analgesics, the responses most often provided were to offer a limited supply 
of short acting opioids or non-narcotic analgesics.  There was a strong aversion to providing long 
acting opioids.  These responses are again consistent with the literature as to current responsible 
prescribing guidelines. 
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 When asked if participants felt pressured to prescribe opioids evening to patients 
exhibiting drug seeking behavior, we found no statistical difference between physicians working 
in for-profit hospitals versus nonprofit hospitals. Specific questions included “Have you, or one 
of your colleagues, been criticized for refusal to prescribe opioids?  (t = -1.198, P = .233), “Do 
you feel a pressure to prescribe opioids, even in the presence of "drug seeking" behavior, to 
avoid patient complaints to hospital administration?” (t = 237, P = .813), and “Do you feel a 
pressure to prescribe opioids, even in the presence of "drug seeking" behavior, to avoid negative 
impact on Joint Commission surveys?” (t = -1.198, P = .233)   Seventy two percent (72%) of the 
participants feel a pressure to prescribe opioids, even when the patient is exhibiting drug seeking 
behavior in order to avoid administrative complaints while 57% feel this same pressure with 
regard to the potential negative effect that refusal to prescribe could have on Joint Commission 
accreditation surveys. 
Regulatory Factors Impacting ED Physician Practices 
 In 1995, when the APS initiated the campaign to view pain as the “fifth vital sign”, the 
management of pain became of much greater importance.  The VA introduced a pain scale and 
results were to be entered into the EMR to raise awareness of changes or satisfaction with pain 
management.  Of great note was when the Joint Commission adopted the idea of pain being 
viewed as the “fifth vital sign.”  At that point, hospital administrations had the expectation that 
ED physicians would insure adequate pain management or risk decreased scores on accreditation 
surveys.  Joint Commission accreditation is crucial to hospitals as not only is it deemed as the 
body overseeing accreditation but reimbursement is directly linked to reimbursement from 
agencies such as CMS.  
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 Submitting to patient’s requests for medication is not a new dilemma for ED physicians.  
For example, the literature is robust with articles addressing the overprescribing of antibiotics.  
Recently the CDC issued a press release speaking to the current and future dangers now 
represented due to antibiotic resistant strains.  Participants were asked to respond to the 
following statement:  “Patients in our culture view drugs as a solution therefore you risk a patient 
complaint if you don’t provide a script on discharge.”  Ninety percent (90%) of the participants 
agreed with 45% strongly agreeing.   
 Regulatory concerns for over- and under-prescribing are well documented in the 
literature.  In reviewing case law on this topic, there were no judgments found against an ED 
physician in these types of cases.  This may support why survey questions regarding civil 
liability concerns were not of significance to participants.  However, in a landmark 
Massachusetts case, a physician was found to be at fault in a civil litigation where the patient lost 
consciousness and was involved in a fatal car accident where a child died.  The physician had 
prescribed an opioid analgesic and the case was decided for the plaintiff based upon a lack of 
warnings being offered to the patient.
33
  This could certainly be a subject for ED physician CME 
in opioid abuse. 
 When asked if participants perceived a pressure to prescribe opioids, to avoid a potential 
Board of Medicine complaint for failure to adequately treat pain, 46% cited concerns.  Of greater 
concern (82%) was a perceived lack of clarity from the Board with regard to the ED physician’s 
course of action should “doctor shopping” be identified.  In a landmark California case, Bergman 
v Chin,
31 the court adjudicated on behalf of a victim’s family in a case of inadequate pain 
management.  What was significant was that the Board had already reviewed the case and 
exerted no disciplinary action. The participants have indicated that they may be less concerned 
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about actions by the Board, but cite the need for recommendations by the Board.   Seventy three 
percent (73%) stated that there are concerns due to lack of clarity in state statues regarding the 
physician’s course of action when confronted with evidence of “doctor shopping.” Other 
regulatory concerns were demonstrated in that 60% of the participants were concerned that 
reporting database confirmed cases where “doctor shopping” was indicated, could result in a 
HIPAA violation.  
The Changing Economic and Healthcare Climates 
 In 2002, CMS initiated what was to become the patient satisfaction survey known as 
HCAHPS.
57
  Patient satisfaction surveys had been administered for many years by vendors such 
as Press Ganey however, the Deficit Reduction Act of 2005 created financial incentives to 
implement HCAHPS which thrust patient satisfaction survey results to a heightened level.   Per 
the Patient Protection and Affordable Care Act of 2010, the provision of HCAHPS data is a 
metric utilized to calculate incentive payments as part of the Hospital Value-Based Purchasing 
program.
58
  This represents a paradigm shift from fee-for-service reimbursement. As an example, 
CMS can withhold 30% of the hospital’s incentive monies should patient scores be 
unsatisfactory.”   This, as in accreditation by Joint Commission are obviously of extreme 
importance to hospitals and therefore a burden now borne by ED physicians as well.  
 As the Great Recession of 2008 occurred, patient volumes have increased significantly.  
ACEP and other entities cite a great percentage represented in the overall increased volume are 
patients receiving Medicaid.
79
  When asked, 91% of the participants indicated that they have 
seen a rise in patient volume over the last two years and 72% have noted a rise in patients 
exhibiting drug seeking behavior.  When queried regarding financial trends, of those participants 
aware of the patient’s method of payment, only 2% had noticed a decrease in government 
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supplied insurance patients exhibiting drug seeking behavior.  The only decrease noted was that 
of private insurance which may coincide with the unemployment and loss of private insurance 
induced by the recession.   
 When asked regarding their opinions as to why patient volumes have increased 84% 
attributed this to reduced availability of opioids subsequent to “pill mill” closures.  Other reasons 
included that less private physicians were accepting Medicare/Medicaid (79%) and less private 
physicians willing to write prescriptions for opioids (68%).  An independent t-test showed that a 
statistically significant number of ED physicians feel that ‘less private physicians accepting 
Medicare/Medicaid’ had an impact on rising patient volumes (t=  -3.068, P=0.003).  A 
statistically significant number of ED physicians also attributed  rising volumes to patient 
awareness that ED’s are obligated to take them as patients. (t= -2.329, P=0.021).   
 With increased volumes comes the need to see increased numbers of patients in lesser 
periods of time.  CMS, in addition to patient satisfaction surveys, is now using “door to 
discharge” metrics as a quality assurance measure and can therefore withhold incentive monies 
should the times exceed those determined.  Participants were asked to give their opinions as to 
the usefulness of patient satisfaction scores as a means of measuring the  quality of healthcare.  
Ninety eight percent (98%) cited that these surveys are too highly emphasized with 78% of that 
number “strongly” agreeing.  Physicians cited feeling a pressure to prescribe opioids, even in the 
presence of drug seeking behavior in order avoid administrative complaints (72%) and due to 
concerns about a negative effect on Joint Commission surveys (61%).  Of significance is that 
40% of the participants had either been criticized, or one of their colleagues been criticized, for 
refusal to prescribe opioids.  The participants in this survey indicated that they feel a need for 
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administration opioids prescribing protocols.  Eight six percent (86%) felt there was no clarity as 
to their course of action when treating a patient confirmed by the PDMP as a “doctor shopper.” 
A little over half of the participants cited that their hospital does support the use of the PDMP 
however three fourths of the hospitals represented by participants do not have an active 
administrative protocol in place.  The majority of participants expressed their  preference for the 
initiation of a protocol with approximately 70% stating they felt this would protect them from 
potential disciplinary action. However, an almost equal number felt that the protocols could 
potentially limit the professional judgment of the ED physician.  
Conclusions 
 The hypothesis is listed with the respective research questions listed below.  A short 
narrative regarding the survey questions, and inferences drawn from the research, will follow as 
will the decision as to accept or reject the hypothesis.   
Hypotheses #1 ED physicians feel pressured to prescribe opioids due to economic 
concerns arising from administrative and regulatory entities.  
 1. Do ED physicians feel pressured to prescribe opioids subsequent to economic  
  influences? 
 2. What economic influences do physicians cite as exerting a pressure on them to  
  prescribe opioids? 
 11. Do ED physicians perceive that regulatory guidelines / statutes are clear as to  
  appropriate pain management for ED patients exhibiting drug seeking behavior? 
 14. Do ED physicians have concerns regarding patient complaints to the Board of  
  Medicine, for under-treatment of pain, should they decline to prescribe opioids? 
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This hypothesis was tested with survey question #29 using relative frequencies.  Participant 
responses suggest ED physicians perceive a pressure to prescribe opioids due to economic 
concerns arising from Board of Medicine disciplinary actions (46%), civil liability (26%), 
administrative complaints (72%) and Joint Commission surveys being negatively affected by a 
refusal to prescribe (57%) and risk of reduced reimbursement (46%).  Therefore Hypothesis #1 is 
supported. 
Hypothesis #2. ED physicians will prefer to have administrative / regulatory opioid 
prescribing protocols for the purpose of protecting them from disciplinary actions.  
 3. What are the perceptions of ED physicians with regard to administrative opioid  
  prescribing protocols? 
This hypothesis was tested with survey questions 36 and 37 using relative frequencies.  
Participant responses indicated that 58% preferred to have an administrative / regulatory opioid 
prescribing protocol.  Therefore Hypothesis #2 is supported. 
Hypothesis #3. There will not be a statistically significant difference between ED 
physicians working in for-profit versus nonprofit hospitals with regard to their perceptions of 
economic pressures from administration to prescribe opioids. 
 1.    Do ED physicians feel pressured to prescribe opioids subsequent to economic  
  influences?       
 2. What economic influences do physicians cite as exerting a pressure on them to  
  prescribe opioids? 
 3.    What are the feelings of ED physicians with regard to administrative opioid  
  prescribing protocols? 
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 7.        Is there a difference in physician opinions, from those who work for for-profit  
  versus nonprofit organizations, with regard to economic pressures to prescribe  
  opioids in order to maintain patient satisfaction scores? 
 14.  Do ED physicians have concerns regarding patient complaints to the Board of  
  Medicine, for under-treatment of pain, should they decline to prescribe opioids? 
This hypothesis was tested with questions #17, 29 and 30.  A t-test was utilized to compare the 
profit versus nonprofit sub-samples.  However, the p values were not greater than 0.05 indicating 
no statistical significance between the two groups.  Specific questions included “Have you, or 
one of your colleagues, been criticized for refusal to prescribe opioids?  (t = -1.198, P = .233), 
“Do you feel a pressure to prescribe opioids, even in the presence of "drug seeking" behavior, to 
avoid patient complaints to hospital administration?” (t = 237, P = .813), and “Do you feel a 
pressure to prescribe opioids, even in the presence of "drug seeking" behavior, to avoid negative 
impact on Joint Commission surveys?” (t = -1.198, P = .233)  Therefore Hypothesis #3 is 
supported.  
Hypothesis #4. Emergency department physicians will cite their failure to use prescription 
opioid abuse identification methodologies is often related to economic factors. 
 4. Do ED physicians refrain from utilizing prescription opioid abuse detection  
  methodologies, such as the Prescription Drug Monitoring Program (PDMP) and   
  drug screening, due to economic factors? 
 5. What rationale do ED physicians use with regard to their decision to cite “opioid  
  overdose” on the patient’s record? 
This hypothesis was tested using survey questions 15, 17 and 20.  A Spearman correlation was 
applied regarding use of opioid abuse identification methodologies.  Low correlations, both 
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positive and negative respectively, specific to use of drug screens and availability (r = 0.393, P, 
0.001), use of drug screens and physician knowledge of how to access the PDMP (r = -0.186, 
P=0.031).   .  Other correlations included low correlations, negative and positive respectively, 
specific to performance of physical examination and avoidance of PDMP utilization, due to fear 
of decreased patient satisfaction should PDMP results indicate “doctor shopping” (r = 0.179, 
P=0.039) and performance of physical examination to detect opioid abuse and physician 
knowledge of how to access database.  (r = -0.174, P=0.045)  Relative frequencies, as discussed 
in this chapter’s opioid abuse identification section, indicate that economic factors play a role in 
the decision of physicians to utilize prescription opioid abuse identification methodologies.  
Therefore Hypothesis #4 is supported. 
Hypothesis #5. Less than 50% of emergency department physicians have received formal 
training, through either continuing medical education (CME) or medical school/post-graduate 
curricula, on recognition and management of prescription opioid abuse. 
  6. Do ED physicians receive formal training on recognition and management of  
  prescription opioid abuse? 
 8. Do ED physicians feel that training on recognition and management of   
  prescription opioid abuse should be part of their training / continuing education? 
Survey questions 6 and 7 were used to test this hypothesis.  Frequencies were used to determine 
the percentage of ED physicians have received formal training in management of prescription 
opioid abuse.  Forty seven percent (47%) indicated that they had received CME training in the 
last three years.  An additional 12% had received training on the topic but more than 3 years ago.  
Therefore Hypothesis #5 is not supported.  
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Hypothesis #6. ED physicians will report they are treating an increased volume of ED 
patients exhibiting drug seeking behavior due to economic and regulatory factors. 
 12. What recommendations do ED physicians have for deterring prescription opioid /  
  controlled substance abuse through actions of the ED? 
 15. Is data regarding morbidity / mortality from prescription opioid abuse patients  
  seen in the ED influenced by economic factors? 
 
Survey questions 26 and 27 were used to test this hypothesis. An independent t-test showed that 
a statistically significant number of ED physicians feel that ‘less private physicians accepting 
Medicare/Medicaid’ had an impact on rising patient volumes (t=  -3.068, P=0.003).  A 
statistically significant number of ED physicians attributed  rising volumes to patient awareness 
that ED’s are obligated to take them as patients. (t= -2.329, P=0.021).  Therefore Hypothesis #6 
is supported.  
Hypothesis #7. There will not be a statistically significant difference between ED 
physicians working in for-profit versus nonprofit hospitals with regard to economic factors (e.g. 
administrative, reimbursement, regulatory) regarding use of prescription opioid abuse 
identification methodologies.  Survey questions 15, 17 and 20 were utilized.  A t-test indicated 
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no statistical significance between the profit and nonprofit groups when asked about the 
physician’s administration’s position regarding use of the PDMP for opioid abuse identification 
purposes. (t = 1.145, P = .254)  Therefore Hypothesis #7 is supported. 
Hypothesis #8.  ED physicians will report a rise in patient volume, including those with drug 
seeking behavior, over the last two years. 
 9. Do ED physicians feel that their volume of patients exhibiting drug   
  seeking behavior has increased in recent years? 
 10. Do ED physicians perceive that there has been an increased volume of   
  patients exhibiting drug seeking behavior that are supported by    
  government insurance such as Medicare / Medicaid? 
 13. Do ED physicians perceive that socioeconomic factors are impacting the   
  volume of patients being seen in the ED exhibiting drug seeking behavior? 
Survey questions 26 and 27 were used to test this hypothesis.  Relative frequencies were 
obtained.  Ninety one percent (91%) of the participants reported a rise in patient volumes in 
general and 72% with regard to patients exhibiting drug seeking behavior.  Therefore Hypothesis 
#8 is supported.  
Recommendations 
 Standardized, ED physician originated opioid prescribing guidelines.  Approximately 
40% of the physicians in this study have either been criticized, or know of a colleague who has 
been criticized for failure to prescribe opioids.  Concomitantly, the results demonstrate that a 
predominance of physicians would prefer to have administrative and/or regulatory guidelines for 
opioid prescribing to avoid disciplinary action.  Standardization of opioid prescribing guidelines 
should be formulated utilizing ED physicians to design the protocol.  Protocols should occur on a 
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national level as this is not only a national problem but it would allow for physicians exiting 
medical schools and residency programs to continue practicing in a manner consistent with their 
training regardless of their new state of practice. 
 
 Modification of Patient Satisfaction Surveys.  Survey procedures should be reviewed.  
Based upon the literature review and research data, there is a potential for both internal as well as 
external validity errors.  Though components of the survey would be helpful for administrative 
purposes, it should not be used as a definitive tool for the evaluation of good medical care. 
ED physicians must have the freedom to provide the patient with the highest level of care, based 
upon their training,  In light of the current prescription opioid abuse epidemic, refusal to 
prescribe may well result in a negative patient satisfaction score yet have a positive healthcare 
contribution.   
 Reduction of Patient Volume by Incorporation of Primary Care.  Utilization of “door 
to discharge” times as a quality measure needs to be evaluated.  A coordinated effort to supply 
primary care or urgent care facilities would detract from the escalating ED patient volumes and 
restore safe physician to patient number ratios.   By segmenting the lesser acuity patients, a more 
rapid standard for door-to-discharge would be realistic.  As termed by one of the respondents in 
the study, emergency medicine is evolving into “assembly line” medicine and lowering of the 
quality of delivered patient care.  Utilization of “patient satisfaction” scores must be 
accomplished with the knowledge that the nature of addiction and drug dependency often 
correlates with non-reliable information.  Refusal by an ED physician to prescribe a 
pharmacologic agent of potential harm may cause the patient to initiate a patient complaint but 
demonstrates good medical care which is the supposed intent of the tool. 
99 
 
 Specialized Training in Management of Prescription Opioid Abuse.  Participant 
responses clearly indicated the need for specialized training in prescription opioid abuse.  
Emergency department physicians share a high exposure to confronting this abuse due to the 
nature of emergency medicine and EMTALA.  The research and literature review are robust with 
educational endeavors for physicians at large as well as pain management specialists.  However, 
ED physicians face a unique set of challenges and education should be specialized to their 
discipline.  Continuing medical education should be mandatory while our country is still in an 
epidemic.  Rather than request additional CME, the hours could be incorporated into current 
CME requirements.   
 Opioid Abuse Identification Methodologies.  The research results and literature review 
demonstrate poor utilization of an epidemiological tool.  By integrating newer programs that can 
interface with EMR and streamline the query process, hopefully there will be greater utilization.  
Additionally, point of care lab testing, with the capability of screening for synthetic opioids, 
could streamline this additional epidemiologic tool. 
Summary 
This original research was initiated to obtain the opinions of ED physicians regarding 
economic and regulatory factors impacting management of patients exhibiting drug seeking 
behavior.  This information can be utilized by medical associations, healthcare organizations, 
regulatory bodies, and public health officials in the development of continuing medical education 
for physicians, curricula for medical schools and residency programs, administrative protocols 
and legislation instrumental to the deterrence of prescription opioid abuse. 
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Appendix B 
 
Survey Consent Form  
Verbal Consent for Interviews  
IRB #9509 Version 1 – February 19, 2013  
Informed Consent:  
 
Thank you for your interest in participating in our research study. Prior to participation, please be 
advised of the following:  
a) The purpose of the study is to obtain the opinions/views of medical professionals managing 
patients on opioid/scheduled drug therapies with regard to management strategies including the 
use of prescription monitoring programs. Opinions will be obtained through an interview.  
b) There are no foreseeable risks, discomforts, or direct benefits of the research to participants. 
All responses will remain anonymous and no identifiable information will be collected by 
researchers.  
c) Data collected will be maintained by researchers on password protected computer systems and 
will not be available for public review  
d) There is no compensation for participation however a 6.5 hour CME video may be viewed on 
a separate website as a means of appreciation for participants’ time in completing the survey. No 
foreseeable costs will be encountered by participants. This study is complete voluntary.  
e) Participants may withdraw from the interview at any time and no questions are mandatory for 
response  
f) I have been informed that I may contact the program coordinator or the IRB office at the 
University of South Florida should I have questions regarding this study. Their contact 
information is:  
1) Sharon Kelley, Study Coordinator, sharon.kelley@aieme.com 813.240.9835  
2) USF Institutional Review Board (IRB): 813.974.5638.  
 
Waiver of Informed Consent:  
This study provides subjects anonymity with regard to their responses thus presenting less than 
minimal risk to the subjects. No identifiable data will be collected through the survey.  
By agreeing to this interview you understand that you are participating in research.  
I consent to participation in this study. 
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